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GENERAL INTRODUCTION: STRUCTURE!FUNCTION RELATIONSHIPS OF AUTOTAXIN
ABSTRACT
Autotaxin (ATX or ENPP2) is an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) 
that functions as a secreted lysophospholipase D to produce the multifunctional lipid mediator 
lysophosphatidic acid (LPA) from more complex lysophospholipids. LPA acts on distinct 
G protein-coupled receptors thereby activating multiple signaling cascades and cellular 
responses. The ATX-LPA signaling axis is implicated in a remarkably wide variety of physiological 
and pathological processes, ranging from vascular and neural development to lymphocyte 
homing, fibrosis and cancer. Despite much progress in understanding LPA receptor signaling, 
the precise mode of ATX action has long remained elusive due to the lack of structural data. 
In particular, it has been unclear what makes ATX a unique lysophospholipase D and how the 
enzyme is targeted to LPA-responsive cells. Recent structural studies have begun to clarify 
these issues. Here we discuss new insights and inferences from the ATX structure.
Jens Hausmann, Anastassis Perrakis & Wouter H. Moolenaar
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1ATXIn 1992, Mary Stracke and cowokers at the NIH were the first to describe an autocrine cell 
motility factor derived from the human melanoma cell line A2058, and named it autotaxin (ATX)1. 
ATX, the product of the ENPP2 gene, is a secreted 125 kDa extracellular glycoprotein, present 
in various body fluids2,3, such as blister fluid4, cerebro-spinal fluid5,6, plasma7, peritoneal fluid8, 
serum9,10, urine10 and synovial fluid11. In 2002, by two independent studies, it became evident, that 
ATX is the plasma lysophospholipase D (lysoPLD)12,13, that hydrolyzes lysophosphatidylcholine 
(LPC) into lysphosphosphatidic acid (LPA) and choline14. LPA is a multifunctional signaling lipid 
that activates many intracellular pathways by binding to specific G-protein-coupled receptors 
(LPA
1-6
)15. The ATX-LPA signaling axis is involved in physiological processes such as proliferation, 
cell survival, wound healing, platelet aggregation, inflammation, as well as vascular and neuronal 
development. It is also associated with multiple pathophysiological conditions, ranging from 
tumor progression and metastasis to fibrotic diseases and neuropathic pain. As a serum-
borne protein, ATX is easily accessible and due to its versatile enzymatic activities to generate 
various LPA species from di"erent substrate precursors, an attractive target for therapeutic 
intervention. It is therefore being studied by academia and industry alike. 
The physiology and pathophysiology of the ATX-LPA signaling axis
The ATX-LPA signaling axis has multiple properties in many physiological processes. Important 
physiological aspects of the ATX-LPA signaling axis have been revealed by the ATX knock-out 
mice, which die at embryonic day 9.5 with severe problems in the formation of functional blood 









account for this phenotype and, moreover, even mice with a triple knockout of LPA
1-3 
did not 
show this phenotypic symptom and were in fact viable17. The single loss of the LPA
1
 receptor 
showed developmental e"ects in the central nervous system and an overall 50% perinatal 
death rate18,19. The constitutive loss of LPA
3
 in mice resulted in delayed and abnormal embryo 
implantation in the uterus20,21. The LPA
3
 receptor is also implied in immature dendritic cell 
migration22. LPA
4
 gene deletion leads to defects in lymphatic vessel development. Further cell 




 knockout is 




 identified its involvement 
in neuropathic pain24. Loss of LPA
6
 is implicated in human hair growth disorders.
Increased levels of ATX have been correlated with cancer, adipogenesis25 and cholestatic 
pruritus26. Additionally, LPA
1
 has been implicated in the initiation of neuropathic pain27 and fibrosis 
in kidney28 and lung29. LPA
2
 has been connected to intestinal cancer30 and lung function in asthma31. 
The homozygous deletion of LPA
6
 has been implicated in bladder cancer development32.
ATX, the ENPP enzyme family and substrate diversity
ATX belongs to the family of ecto-nucleotide pyrophosphatasen/phosphodiesterases (ENPPs), 
which encompasses seven family members (ENPP1-7)33. ATX is the second family member and 
therefore also known as ENPP2. The enzyme family can be divided into two subgroups, namely 
ENPP1-3 and ENPP4-734. ENPP1-3 share the principle domain arrangement of two N-terminal 
somatomedin B (SMB)-like domains, a central catalytic phosphodiesterase (PDE) domain 
and a C-terminal inactive nuclease (NUC)-like domain. The second subgroup, ENPP4-7, has 
9
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only a single PDE domain in common33,34. Apart from ATX, which is exclusively secreted35, the 
remaining six family members can be found on the cell surface, either as type-I (ENPP4-7) or 
as type-II (ENPP1 and ENPP3) transmembrane proteins (Fig.1)33,36-39. Furthermore, ENPP1 was 
recently found to exist as a secreted fraction next to the membrane bound form40. This study 
also revealed that secreted ENPP1 is the putative consequence of an intracellular proteolytic 
processing, which chops o" the N-terminus till Lys85, including the transmembrane region.
The substrate specificity of the ENPP family members is very diverse: ENPP1-3 recognize (di)
nucleotides and their derivatives, as well as lysophospholipids in case of ATX (lysophospholipase 
D activity)33. ENPP6 and ENPP7 accept choline phosphate ester substrates like LPC, but they 
hydrolyze it to monoacylglycerol and choline phosphate (lysophospholipase C activity). At 
present, the substrates of ENPP4 and ENPP5 are not known (Fig. 1). 
ATX produces LPA from a diverse set of lipid substrate precursors like the LPC, but also from 
lysophosphatidylserine (LPS) and lysophosphatidylethanolamine (LPE). It does not seem to 
discriminate between the lipid headgroups (Fig. 2), as indicated by roughly the same catalytic 
e#ciency41,42. Apart from the headgroup, the lysolipid substrates of ATX vary not only in acyl 
chain length and saturation, but also in the position of the acyl chain substitution (sn1 vs. sn2). 
Moreover, ATX can also hydrolyze sphingosylphosphorylcholine (SPC) into sphingosine1-
Fig. 1: Schematic domain presentation of ENPP enzyme family. The domains (middle column) are colored 
according the legend for the individual ENPP member (left column). The known substrates for each family 
member are indicated in the right column. This figure is adapted from Stefan et al., 2005.
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1
Fig. 2: Accepted substrates of ATX. (a) Diversity of lipid substrates for the hydrolysis by ATX to generate 
LPA. (b) Diversity of the nucleotidic substates. The red arrows indicate the bonds that ATX cleaves. 
Alternative bond cleavage sites are presented with a second red arrow. 
11
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phosphate (S1P). S1P is chemically similar to LPA and shows comparable signaling properties. 
However, S1P stimulates its own G-protein coupled receptors, termed S1P
1-5
. Currently, there 
exist no evidence that ATX generates S1P in vivo, as S1P is mainly considered to be produced by 
the phosphorylation of sphingosine by sphingosine kinase43. Furthermore, at least in vitro, ATX 
shows catalytic activity towards nucleotides and their derivatives, accepting natural substrates 
such as ATP, UDP-glucose, NAD+, Ap
n
A, and 3’Phosphoadenosine-5’-phosphosulfate (Fig. 2)44,45.
The isoforms of ATX
In mice and humans, four di"erent isoforms of ATX, namely ATX !, ", # and $, are detected46,47. 
These isoforms result from alternative splicing of ENPP2, which generates human ATX! with 
a length of 915 aa, ATX" with 863 aa, ATX# with 889aa and ATX$ with 859 aa. These splicing 
variants of ENPP2 are characterized by a lack of exon 21 for ATX! and of exon 12 for ATX#. 
ATX" and ATX$, both miss exon 12 and 21. All four isoforms of ATX are di"erentially expressed. 
ATX! shows the overall lowest expression in the central nervous system and in the peripheral 
tissue. ATX" is the best-studied isoform of ATX with high expression in the peripheral tissue 
and lower expression in the central nervous system. ATX# is mainly expressed in the central 
nervous system. Within the group of ATX isoforms, ATX! catches one’s eye, as it has a 52 amino 
acid long polybasic insert in the middle of the catalytic domain, including a functional protease 
cleavage site. The insert of ATX! is shown to be cleaved by the endoprotease furin, however 
ATX! remains functionally intact, as observed by comparable enzyme kinetics of ATX! and ". 
After proteolytic cleavage the overall structural stability of N- and C-teminal fragments of ATX! 
is secured by an extensive interface. This interface is stabilized by van der Waals, hydrogen and 
ionic interactions, as well as an interfragmental disulfide linkage.
Overview on the crystal structures of ATX
The domain structure of ATX comprises known folds, but in silico predictions have failed to 
model the relative domain orientation correctly48. The surprisingly compact architecture of ATX 
was revealed by the crystal structures (Fig. 3)49,50. The central element of the ATX structure is the 
PDE domain, which interacts with both SMB domains on one side and the NUC domain on the 
opposite side, giving ATX a plate-like three-dimensional appearance. The domain arrangement 
between the PDE and NUC domain is stabilized by four important structural features, namely 
(i) the interdomain disulfide bond and (ii) the “lasso loop” (iii) the N-linked glycan chain at 
Asn524 (iv) the C-terminal !-helix. The disulfide bridge between Cys413 and Cys805 also 
connects the PDE domain directly to the Nuc domain49-51 and has a crucial contribution to 
the fold stability of ATX. The “lasso-loop” extends from the end of the PDE domain and wraps 
almost around the entire NUC domain. Both, the essential glycan chain of Asn524 and the 
C-terminal !-helix (residue 844-859) reinforce the stability of the fold by contributing to the 
generation of an extensive hydrogen bonding network in the interface between the PDE and 
NUC domain49,50,52. Due to these structural features, the connection between the PDE and NUC 
domain is stabilized49,50. The fold of the PDE domain of ATX is energetically unfavorable and 
most likely unstable. Thus, evolution had to select for these interactions to ensure a functional 
enzyme. The ATX structure represents beautifully the long way nature undertook to evolve it.
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1The catalytic phosphodiesterase domain and the active siteAll ENPP family members share a common catalytic PDE domain of about 400 amino acids (Fig. 1)33,44,36. 
So far structural data of ENPP family members are only available for ATX49,50 and the recently solved 
crystal structures of ENPP140,53. Both ATX and ENPP1 have a PDE domain fold that is similar to other 
members of the alkaline phosphatase (AP) superfamily45,53. The AP superfamily groups a diverse 
set of metalloenzymes54, such as the nucleotide pyrophosphatase from Xanthomonas axonopodis 
((XaNPP) (2GSN))55, but also the name-giving member of the AP superfamily from Escherichia coli56. 
The architecture of the active sites of ATX and ENPP1 around the Threonine nucleophile, including 
the two zinc ions and their coordination shell, is structurally comparable to the active site of XaNPP. 
The metal ions coordination shell of ATX is constructed by three aspartates (Asp171, Asp311 and 
Asp358) and three histidines (His315, His359 and His474). All ENPP family members have conserved 
residues at these positions and moreover the active site residue threonine is also conserved 
within ENPP1-5 and ENPP7. ENPP6 has a serine as catalytic residue, which is a structural common 
feature of other members of the AP superfamily. Interestingly, these family members preferably 
hydrolyze phosphomonoesters. These similarities could suggest a conserved two-step in-line 
displacement mechanism for ATX and ENPP1, in accordance with other phosphodiesterases and 
alkaline phosphatase family members (chapter 3)40.
The substrate binding site of ATX 
The hydrophilic binding groove next to the active site is a further structurally conserved element 
between ATX, ENPP1 and XaNPP. For XaNPP, the hydrophilic binding groove was shown to bind 
the ribose and base moieties of nucleotide products55 and in ATX it accommodates the glycerol 
backbone of the lipid products50. This shallow groove extends into a hydrophobic pocket, about 
15 Å in depth57, which is not present in ENPP1 and XaNPP. It is considered to originate from a deletion 
of an 18-amino acid stretch that is specific to ATX within the ENPP family40,49,50. The absence of this 
deletion in other ENPP family members, suggests that these enzymes posses neither a pocket, 
nor a tunnel and accordingly, ENPP1 lacks both structural elements of ATX40,49,50. 
The crystal structures of ATX complexed with LPA molecules of di"erent chain length 
and saturations have shown that the hydrophobic pocket binds the lipid acyl chain in distinct 
conformations50. These studies revealed that LPAs with saturated alkyl chains (e.g. 16:0, 18:0) bind 
in the hydrophobic pocket in a more elongated fashion. In contrast to LPAs with unsaturated chains 
(e.g. 18:1, 18:3 and 22:6), which have a more bent conformation, most likely due to the rigidity the 
carbon carbon double bond. In case of the ATX-LPA (22:6) complex structure, the aliphatic chain 
is even positioned in a U-shaped conformation in the hydrophobic pocket. It would be of interest 
to understand the lipid substrate binding properties of ENPP6 and ENPP7, as both enzymes are 
expected to lack a hydrophobic pocket, while still being able to hydrolyse lipid substrates like LPC. 
At least in vitro, ATX shows catalytic activity towards nucleotide substrates, although 
weaker than ENPP140. Currently, there are no structural complex data available for both ENPP1 
and ATX, bound to a nucleotide. However, superposition of ATX and ENPP1 to the AMP-bound 
complex of XaNPP (PDB 2GSU) might suggest a functionally important role of a loop region40. 
This loop is disordered in ATX, while in ENPP1, the corresponding region is well ordered in crystal 
structure and in close proximity to an active site bound phosphate40. It is suggested that this 
loop might explain the higher catalytic e#ciency of ENPP1 over ATX to hydrolyse nucleotide 
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substrates, by functioning as “phosphate-capture loop” that could be important for substrate 
binding to shield the phosphate groups from solvent40. Nevertheless, structural binding study 
data of nucleotidic substrates and products for ENPP1 and ATX are indispensible to grasp the 
underlying catalytic mechanisms.
The SMB domains of ATX
SMB domains are relatively small and cysteine-rich domains, which are known to mediate 
protein-protein interactions. ATX, as well as ENPP1 and ENPP3 have tandem C-terminal SMB 
domains (SMB1 and SMB2), while ENPP4-7 lack both SMB domains44. The known X-ray and 
NMR structures of the SMB domain from the plasma protein vitronectin (vSMB) are consistent 
with the principle domain organization of the SMB domains from ATX (chapter 3). The domain 
organization is achieved by an intrachain disulfide knot with all eight cysteines being arranged 
in four pairs of crossed disulfide bonds44,49,58, which is in agreement with ATX and ENPP140,49,50. 
In ATX, the SMB1 domain binds to the PDE domain with a similar surface as the vSMB binds 
to the plasminogen activator inhibitor-1 (PAI-1) and the urokinase-type plasminogen activator 
(chapter 3). The SMB2 domain of ATX binds to platelet integrins in a "3-dependent manner49,59. 
A truncated version of ATX, which only contains the two SMB domains, could still bind to 
activated platelets49. Furthermore, it was shown that the SMB2-mediated complex formation of 
ATX and platelets integrins accelerates the LPA generation59. Currently, it is still unclear how this 
is exactly achieved on molecular level.
Initially, for ENPP1 the SMB domains were considered to be involved in the homodimerization 
via interchain disulfide bridges60,61. However, recent investigations indicate that the dimerization 
Fig. 3: The structure of ATX shown as secondary structure representation. Distinct domains are colored 
according to the scheme in Fig. 1. Crucial structural stability elements are highlighted in gold. Side chains 
of important active site residues and zinc ions are depicted in the PDE domain. The image was generated 
using PyMOL (www.pymol.org) (PDB entry: 2XR9).
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1is more likely facilitated by transmembrane disulfide bond formations
40. Consistently, neither 
ATX nor ENPP3 are so far known to dimerize, although both enzymes possess SMB domains. 
Both SMB domains of ATX are connected to the PDE domain via extensive interactions, which 
locate them in close proximity to the active site, in contrast to the observed SMB domains of 
ENPP1 that point away from the PDE domain in one monomer of the crystallographic dimer. 
The SMB domains of the second ENPP1 monomer in this crystal structure disappear in the 
bulk solvent40. These observations suggest a high flexibility of both SMB domains of ENPP1, 
contradictory to the rigid orientation of the SMB domains observed in di"erent crystal packings 
of ATX49,50. Nevertheless, this stable interaction between the SMB1 and the PDE domain in ATX 
allow the formation of the tunnel, which is suggested to be an important structural feature of ATX.
The tunnel of ATX
An unexpected and intriguing observation revealed by the crystal structures is the tunnel of 
ATX49,50. It spans from the active site to the opposite side of ATX (Fig. 4). It connects to the 
hydrophobic pocket and the catalytic site, thereby shaping the formation of a ”T-junction”34,57. 
Residual electron density in the tunnel was detected by Nishimasu et al. and us; however, 
so far this density was not unambiguously modelled. Nishimasu and colleagues used mass 
spectrometry and detected LPA in their protein preparation used for the crystal structure 
determination. Additionally, these researchers explored the function of the tunnel by the 
generation of insertion mutants (LI1-3), which were predicted to occlude the tunnel. When 
Fig. 4: The structure of ATX shown as a surface representation. Distinct domains are colored according 
to the scheme in Fig. 1. Lower panels: the hydrophobic lipid binding pocket and the open tunnel in the 
catalytic domain are depicted as close-ups. The Thr nucleophile is colored in red. The images were 
generated using PyMOL (www.pymol.org) (PDB entry: 2XR9). See text for further details.
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compared to wildtype ATX, these mutants had similar nucleotide hydrolysis activities towards 
pNP-TMP and reduced, but significant lysoPLD activities. Strikingly, the LI1-3 mutants showed 
impaired cell motility. Based on these results, it was concluded that the tunnel might function 
as an LPA product binding site and that LPA is specifically delivered to its GPCRs via exiting 
through the tunnel50. It is tempting to speculate (based on the close proximity and accessibility 
of the tunnel to the active site) that it may function as a substrate entry tunnel or product exit 
channel34,49,57, however, a functional role of this unique tunnel still has to be demonstrated. 
Potential cell surface immobilization routes of ATX
LPA production is expected to be spatially and temporally tightly regulated57. One way to achieve 
this can be via the binding of ATX to target cells and thereby producing specific LPA species at 
the site of action. Di"erent scenarios could fulfill such an immobilization and it was already 
shown that ATX binds to surface exposed integrin molecules49,59. The immobilization of ATX via 
the binding to cell surface proteoglycans to like heparan sulfate and the direct association of 
ATX to its cognate GPCRs are hypotheses that remain to be experimentally addressed. 
ATX binding to cell surface integrins
Integrins are cell-surface receptors, which are composed of an !- and "-subunit. In mammals, 
18 ! and eight " subunits are known, forming a combination of 24 unique integrins62. These 24 
integrins mediate cell-cell, cell-extracellular matrix, and cell-pathogen interactions and have 
been found to have a pivotal role in leukocyte recruitment, phagocytosis and immunological 
synapse formation63,64. Their bidirectional signaling molecule character allows them on one hand 
to transduce a signal from outside of the cell into the cytosol (outside-in signaling) and on the other 
hand they can also signal from the cytosol into the extracellular space (inside-out signaling)63. 
The integrin’s structure can undergo a conformational change from low to a high ligand a#nity 
state for ligands. The low-a#nity state is characterized by an inverted v-shape or bent structure 
of the extracellular domains, while in the high-a#nity state the structure resembles an extended 
conformation, pointing out far into the extracellular space62. Switching from low to high ligand 
a#nity is also known as the activation of integrins. This activation is crucial for the modulation 
of the extracellular ligand a#nity62. Generally, the activation of integrins is dependent on the 
disruption of the non-covalent clasp between the ! and " cytoplasmic integrin tails65. In a "3 
dependent context, the binding of talin to the cytoplasmic integrin domain can achieve this 
disruption65,66. It was recently revealed that the intracellular G-protein G!
13
 binds integrin "1 and 
"3 subunits and mediates integrin outside-in signaling in platelets67, supporting the concept of a 
tight regulation of G-protein subunit and the activation of integrins.





Kanda et al. were the first to suggest a complex of ATX to an integrin, namely !4"1, which is 
expressed on leukocytes68. This complex formation is thought to be an important step in the 
recruitment of leukocytes to inflamed tissue68,69. Leukocyte recruitment is a multi-event cascade, 
including the capturing and rolling of leukocytes, mediated predominately by selectins, the 
slow rolling and arresting to the microvascular endothelium, mainly assured by integrins and 
finally the transmigration into the site of the cellular destination facilitated by PECAM64,70. During 
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1the rolling of leukocytes over endothelium, immune cells are exposed to ligands that trigger G-protein dependent pathways64. It is thinkable that specific G-protein subunits subsequently 
modulate an inside-out signaling event on particular integrins of leukocytes and in turn, the 
integrins get activated, which leads to high ligand a#nity during adhesion.
Until now, the mode of the interaction between ATX and leukocytes is not clear, but it may 
happens via the canonical !4"1 458LDV460-motif on ATX57. However, the fact that the formation 
of the interaction of ATX with leukocytes cannot be inhibited by either integrin-specific 
antibodies against "1, "2 and !4, nor integrin-binding peptides (RGD and LDV)68, argue for an 
alternative molecular interaction.
ATX complexed to !IIb"3/!%"3
ATX interacts with integrins from platelet and CHO cells in a "3 subunit dependent manner49,59,71. 
Two di"erent "3 containing integrins are localized on the surface of platelets, which are several 
hundred molecules of !v"3 and about 80000 !IIb"3 molecules per platelet72. Many members of 
the integrin family, including !5"1, !8"1, !v"5, !v"6, !v"8, but also !v"3 and !IIb"3 recognize an 
Arg-Gly-Asp (RGD) motif within their ligands73. However, residues outside the RGD motif often 
provide specificity as well as high a#nity for each integrin-ligand pair74. ATX contains a 127RGD129-
motif in the SMB2 domain and noteworthy even when mutated to AGA the binding to platelet 
integrins is only marginally reduced49. Alanine mutations of Glu109 or His119 show a significantly 
lower binding of ATX to activated platelets49,59 and CHO cells overexpressing the "
3
 subunit59. 
ATX! binding to heparin
Another possible way for ATX to bind to target cells is via the immobilization on cell surface 
proteoglycans. A recent report could show an isoform-dependent, specific binding of ATX! in 
a low nanomolar range to heparin, whereas binding of ATX" could hardly be detected (Houben 
et al., JBC 288: 510-519, 2013). Interestingly, in these investigations it was reported that the 
binding of heparin accelerates the lysoPLD activity of ATX! up to two-fold, which could be a 
result of a lower K
d
 value for LPA (18:1) and thus higher catalytic e#ciency. 
Currently, structural data are only available for ATX" and ATX$. Both isoforms do not 
posses this insert. It would be of interest to obtain structural insights of ATX! to understand 
how the insert exactly mediates high a#nity binding to heparin. However, the former 
described experiments demonstrate the need to test if ATX! binds to heparan sulfate or other 
proeteoglycans on the cell surface. 
ATX binding to GPCRs?
Another hypothetical, but nevertheless tempting mechanism to speculate on, is the 
immobilization of ATX via binding to LPA
1-6
 receptors. According to this concept the tunnel of 
ATX is thought to support the delivery of LPA to its receptors by functioning as a substrate entry 
or product exit tunnel. Recently this concept is challenged by structural data from Hanson et al. 
of the S1P
1 
receptor75. These researchers found that the lipid binding pocket of S1P
1
 is buried in 
the plasma membrane without an extracellular entry possibility and therefore suggest a likely 
delivery of S1P into the outer leaflet of the plasmamembrane, a subsequent lateral di"usion of 
S1P in the cell membrane and an resulting entry into the binding pocket of S1P
1
, that is formed 
17
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by the helical segment 1 and 775. In helix 7 Arg292 is of particular interest and it was suggested to 
support the guidance of the S1P into the binding pocket by functioning as cationic lure, which 
could direct the lateral di"usion of phospholipids ligands towards the binding pocket76. Further 
experiments will have to validate whether this concept holds also true for the LPA delivery to its 
receptors and whether ATX has or has not a role in this delivery.
ATX Inhibitors
The upstream position of ATX in the capability to produce of a variety of LPA molecules to 
modulate a multitude of signaling pathways, as well as the easy accessibility of this serum-
derived enzyme, makes it an interesting target for therapeutic intervention and therefore it 
is being targeted by academia and pharmaceutical industry likewise. Many small molecule 
inhibitors have been reported in academic and patent literature and these inhibitors have been 
reviewed elsewhere45. However, surprisingly only two nanomolar inhibitors, called HA13077 and 
PF838078, were tested for their e#ciency in vivo so far and at the moment structural data are 
only available for HA15549, an inhibitor based on further development of HA13045,77. ATX binds 
HA155 in a specific way as its warhead boronic acid forms a low energy covalent bond to the 
O# of the active site residue Thr20949. At the other end of HA155, the hydrophobic fluoro-
benzene ring is accommodated the hydrophobic lipid binding pocket of ATX49. Unfortunately, 
further specific interaction of ATX with other small molecule inhibitors such as PF8380, are not 
known yet, due to the lack of structural data. However continuous scientific endeavors will 
surely accelerate structural advances of inhibitor driven binding modes to ATX, which will lead 
to further optimized small ligand inhibitors. 
18
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ABSTRACT
Autotaxin (ATX or ENPP2) is a secreted, glycosylated mammalian enzyme that exhibits 
lysophospholipase D activity, hydrolyzing lysophosphatidylcholine (LPC) into the signalling 
lipid lysophosphatidic acid (LPA). ATX is a ~100 kDa multi-domain protein, encompassing 
two N-terminal somatomedin-B-like domains, a central catalytic phosphodiesterase domain, 
and a C-terminal nuclease-like domain. We report protocols for the e#cient expression of 
ATX in amounts su#cient for crystallographic studies, from stably transfected mammalian 
HEK293 cells. Purification resulted in protein that crystallized readily, but various attempts 
to grow crystals suitable in size for routine crystallographic structure determination were 
not successful. The available micron-thick plates however di"racted X-rays beyond 2.0 Å 
and allowed collection of complete di"raction data to about 2.6 Å resolution. We discuss the 
problems we encountered, and the current advantages and limitations for di"raction data 
collection from thin crystal plates.
Jens Hausmann1, Evangelos Christodoulou1, Mobien Kasiem, Valeria De Marco,
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INTRODUCTION
Autotaxin (ATX), the second member of ecto-nucleotide phosphodiesterase/pyro-
phosphatase family (ENPP), is a secreted ~100 kDa glycoprotein 1. ATX/ENPP2 is classified as 
a phosphoric diester hydrolase (EC 3.1.4) that displays alkylglycerophosphoethanolamine 
phosphodiesterase (lysophospholipase D) activity2 (EC 3.1.4.39). Autotaxin converts extracellular 
lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA), a signalling phospholipid 
acting on at least six distinct G protein-coupled receptors (LPA
1-6
) and eliciting a great variety 
of both short-term and long-term cellular responses3. ATX and LPA signalling are strongly 
implicated in tumour progression and metastasis, as well as in inflammation, fibrotic disease 
and neurological disorders4-6. As such, ATX holds great promise as a therapeutic target 7. 
ATX harbours a central catalytic domain similar to bacterial phosphodiesterases and alkaline 
phosphatases. This domain is flanked N-terminally by two Cys-rich somatomedin-B-like (SMB) 
domains, and C-terminally by a nuclease-like domain. The intact secreted protein is needed for 
activity and glycosylation has been shown to be crucial for function 8. We have therefore set out 
to make ATX in amounts su#cient for crystallographic studies.
Protocols for overexpression of secreted proteins in amounts suitable for crystallographic 
studies have been established as part of the SPINE consortium9. We adapted these protocols 
and extended them for use of stably transfected cell lines.
Although ATX was easy to crystallize once produced in homogenous form and good quantity, 
we could only obtain micro-crystals. Despite older10,11 and more recent advances12-15 in micro-
crystallography, data collection from plate-like crystals presented a challenge which we discuss.
EXPERIMENTAL PROCEDURES AND RESULTS
Construction of a stable cell line expressing ATX
A rATX construct retaining only one glycosylation site essential for activity8 was amplified 
by PCR from plasmid DNA (using 5’-TGGTACCGCCACCATGGCAAGACAAGGCTGTCTC-3’ 
and 5’-ACCGGTAATCTCGCTCTCATATGT-3’ primers) and the reaction product was cut 
with Asp718I and AgeI restriction enzymes, and cloned into the plasmid pcDNA3.1/V5-His 
(Invitrogen) to introduce a C-terminal His6 tag. The rATX-His gene was amplified by PCR, 
(using 5’-TGGTACCGCCACCATGGCAAGACAAGGCTGTCTC-3’ and 5’-GGATCCTCAATGGTGA 
TGGTGATG-3’ primers), cut with Asp718I and PinAI restriction enzymes and cloned into the 
plasmid pcDNA5/FRT. Restriction digests were performed for 1h at 37o. PCR reactions were 
performed using Pfu (Stratagene Cat. Nr. 600353-51) polymerase in 50 µl reactions volumes, 
using 30 PCR cycles (denaturation 96o for 30s, annealing 55o for 30s, 72o for 120s). All other 
conditions were according to manufacturer instructions and reaction bu"ers supplied by the 
manufacturer. The final clone was verified by sequencing.
HEK 293 Flp-In cells (Invitrogen) were grown in 10-cm tissue culture dishes in DMEM 
medium (Invitrogen, Cat. Nr. 41966-052) containing 10% FCS (Sigma, Cat. Nr. 8200496835) and 
100µg/ml Zeocin (Invitrogen, Cat. Nr. 45-0430). On the day of transfection, the cells (80-90% 
confluent) were washed with medium without Zeocin and co-transfected with 2µg pcDNA5/
FRT-rATX-His and 18µg pOG44 (Invitrogen Cat. Nr. K6010-01) using lipofectamine (Invitrogen 
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Cat. Nr. 18324012). Next day the cells were washed using fresh medium without antibiotics. The 
following day the cells were split to ~20% confluence in fresh medium containing 100µg/ml 
Hygromycin B (Invitrogen, Cat. Nr. 10687-010) and allowed to grow for approximately ten days 
until foci could be identified. Six foci were picked and expanded in T175 tissue culture flasks 
in DMEM medium containing 10% FCS and 100µg/ml Hygromycin B, to verify resistance in 
Hygromycin B. Cells were flash frozen in liquid nitrogen for future use.
Large scale expression 
For large scale expression, cells were first grown in T175 tissue culture flasks in DMEM medium 
containing 10% FCS and 100µg/ml Hygromycin B. Cells were grown to 80-90% confluence, 
washed twice with fresh DMEM medium, and transferred to roller bottles (GreinerBioOne, Cat.
Nr. 681070). Typically a single T175 flask was used to inoculate one roller bottle and the cells 
were cultured for four days after transfer into 125 ml of DMEM containing 10% FCS. The medium 
was changed to 125 ml DMEM supplemented with 2 mM Glutamate (GIBCO, Cat.Nr. 25030-123) 
and the cells were then left to express protein for four days. The medium was collected and the 
cells were supplemented with fresh medium and left to express protein for a further four days. 
Purification of secreted ATX
The medium was collected, and filtered through a 0.45 µM bottle-top filter. The filtered medium 
was subsequently applied to a ~10ml POROS-20 MC column, pre-loaded with Ni+2, at a flow rate of 
10-15 ml/min. The column was washed with eight to ten column volumes of Bu"er A (20 mM Tris/
HCl pH 8.0, 150 mM NaCl and 10-20 mM imidazole). The protein was eluted with a short (2-3 column 
volumes) linear gradient to Bu"er A containing 750 mM imidazole. The rATX fractions were mostly 
pure, with the exception of a ~200 kDa band. To remove this band the pooled fractions were 
concentrated and subsequently applied to a Superose 6 10/30 size exclusion column in Bu"er A. 
rATX eluted as a single symmetric peak at a column volume corresponding to a monomer of ~100 
kDa. The peak fractions were pooled and concentrated to ~3-4 mg/ml for crystallization. 
Concentration posed a serious practical problem, as rATX would ‘stick’ in most commonly 
used centrifugal filters, preventing concentration. We initially resorted to dialysis against 30% 
PEG 10,000 to concentrate the protein. The use of Ultra-15 (Amicon, 10 kDa MWCO) centrifugal 
filters however, allowed more e#cient concentration later in the course of the project. 
Preparation of eight roller bottles typically allowed 2-3 mg of protein to be produced.
Crystallization
rATX was initially crystallized by vapour-di"usion in nano-drops using the protocols summarized 
in16. Crystals in the shape of microscopic plates appeared in many conditions in the PACT screen 
(described in16 and manufactured by Qiagen). All conditions that produced initial hits contain 
PEG by definition, and given the highly redundant nature of the PACT screen, hits appeared in 
about ten drops; the conditions giving the best crystals were: (B5) 0.1 M MIB bu"er pH 8, 25% 
w/v PEG 1500; (B6) 0.1 M MIB bu"er pH 9, 25% w/v PEG 1500; and (E11) 0.2 M Sodium citrate, 20% 
w/v PEG 3350. Various attempts to improve the size of these crystals failed; the biggest crystals 
that we were able to grow in these conditions were plates of several tenths of microns across, 
but sub-micron thick at best.
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After additive screening, octanoyl-N-methylglucamide (MEGA-8) appeared to have 
a positive e"ect on crystal size. Crystallization in very large drops of a total volume of 10 µl 
produced plate-like crystals of excellent morphology, where the smallest dimension was 
estimated to be just above 1 micron, Table 1.
Following optimization of the rATX purification protocol additional optimization showed 
that micron-thick crystals could be grown, without a need for detergent or large drops, in 
standard SBS format crystallization plates in drops of 300 nl total volume using the Mosquito 
liquid handling robot. The presence of phosphate ions at concentrations 20-200 mM was crucial 
for formation of these crystals, which appeared over a wide pH range, and had a morphology 
identical to the ones produced in the presence of detergent, Table 1. These crystals were 
formed with or without seeding, although seeding accelerated crystal formation.
In both crystallization protocols, higher concentration of protein correlated well with 
increased crystal size. However, the practical yields of protein did not allow concentration 
above a certain limit, which was maximally ~5 mg/ml.
Although we have successfully produced Se-Met substituted protein in the stable HEK-293 
cell line, yields were significantly lower due to the toxicity of the Se-methionine, which 
precluded concentrating the protein enough for growing crystals of size similar to the native. 
Crystals were transferred to a solution typically containing 20-25% glycerol in addition to 
the mother liquor, and mounted in loops. All were vitrified by plunging them in liquid nitrogen, 
mounted in ‘SPINE’ pins and transferred into SPINE/ESRF pucks for shipment and data collection 
at the synchrotron17. During the course of about two years, a couple of thousand crystals were 
mounted, and about a third of these attempts gave single crystals in the loop. Roughly five 
hundred crystals were tested for di"raction. In total about thirty datasets were collected, and 
the best data are presented in this paper. The crystals used for these data are shown in Figure 1.
Collection of di!raction data and analysis
We discuss the measurement of three datasets: two are collected from crystals grown from 
very large crystallization drops (10µl), one with a micro-beam (10x10 µm) and one with a 
Fig. 1: The crystals used for data collection. (A) ‘Crystal 2’, exposed at the SLS in the crystallization drop 
and (B) ‘Crystal 3’, exposed at Diamond as seen at the beamline mounted in a loop and flash-frozen.
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Table 1: Sample information
Macromolecule details ENPP2/ATX
Mass (Da) 98,000
Source organism  Rattus norvegicus




Sitting -drop vapour 
di"usion
Sitting -drop vapour 
di"usion
Temperature (K) 293 293 293
Crystal growth time 4-5 days 4-5 days 2 days
Crystallization solutions
Macromolecule
4 µl, rATX (3-4 mg ml -1), 
NaCl (150 mM), tris 
hydrochloride (pH 8, 
20 mM)
4 µl, rATX (3-4 mg ml -1), 
NaCl (150 mM), tris 
hydrochloride (pH 8, 
20 mM)
200 nl, rATX (3-4 mg 
ml 1), NaCl (150 mM), 
Tris/HCl (pH 8.0, 20 
mM)
Precipitant
5 µl, polyethylene 
glycol 6000 
(20%(w/v)), potassium 
citrate (100 mM), MIB 
bu"er (pH 8.5, 100 mM)
5 µl, polyethylene 
glycol 6000 (18-22%(w/
v)), potassium citrate 
(100 mM), MIB bu"er 
(pH 8.5, 100 mM)
100 nl, polyethylene 
glycol 3350 
(±20%(w/v)), Bis Tris 
propane (pH 6.5-8.5, 
100 mM)
Additive 1µl of 1 M MEGA-8/10 1µl of 1M MEGA-8/10 20-200 Na/K PO
4
Crystal data
Crystal size (µm) ~ 100 % 50 % 1 ~ 150 % 30 % 1 ~ 200 % 30 % ~1
Matthews coe#cient, V
M
 (Å3 Da-1) 2.38 2.38 2.38
Solvent content (%) 48 48 48
Unit-cell data


















a, b, c (Å) 95.3, 121.8, 158.4 96.2, 121.7, 160.0 95.4, 120.2, 157.1
a, b, g (°) 90, 90, 90 90,90,90 90, 90, 90
No. of molecules in unit cell, Z 2 2 2
typical size beam (40x100 µm); the third dataset was collected from crystals grown in small 
crystallization drops (0.3 µl).
SLS data collection with a micro-di!ractometer
A good quality crystal was obtained after extensive screening at the SLS X06SA beamline (PX1) 
in the setup equipped with the EMBL/ESRF micro-di"ractometer11 and a 10 µm beam-defining 
aperture. Based on experience from previous crystals, we knew they had a limited lifetime. 
The longer dimension of the crystal was oriented along the rotation axis, to allow translation 
between successive ‘wedges’ and minimize radiation damage. The first ‘wedge’ of thirty 
degrees was collected ‘edge-on’, while the last twenty degrees were collected ‘face-on’. It can 
be seen in Figure 2A and B that in the edge-on orientation the di"raction is strong but spots are 
imperfect due to crystal imperfections along the long plate axis fully bathed in the beam, while 
in the ‘face-on’ orientation the di"raction is significantly weaker, but the spots are very small, 
round-shaped with clear edges, since only a very limited volume of the crystal is exposed. This 
strategy resulted in a dataset of good quality; the spot intensities were integrated in MOSFLM, 
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using the ‘RESOLUTION CUTOFF 1.0’ keyword, that limits the radial integration area in each 
image to the resolution bin that the average I/sig(I) fell below 1.0. The resulting dataset was 
complete to about 3.2 Å resolution, and had useful data to 2.6 Å resolution (Table 2).
SLS DATA COLLECTION WITH A ‘TYPICAL’ BEAM AND A PILATUS 
DETECTOR.
At a later data collection trip, a crystal of similar quality, but possibly exceeding 1 µm in thickness, 
was identified. At that time we were using the SLS ‘high-resolution di"ractometer’ with a beam 
of approximately 40x100 µm and we were aware that we were missing ‘face-on’ data from the 
previous dataset. We were able to only collect 25 degrees of data before the crystal su"ered 
from radiation damage. The data quality statistics for this ~50% complete dataset (Table 2) 
demonstrate that the crystal plates were of excellent quality with minimal distortion around 
their surface. We observed that our crystal could withstand a higher X-ray dose in the shutter-
less data collection mode enabled the Pilatus 6M detector18, than in the same beam with the 
same exposure and a normal CCD detector.
A combined native data and obstacles in collecting a Se-Met dataset.
Combining the above data, we obtained a dataset to 2.6 Å resolution, (Table 3). This dataset 
had improved completeness, specifically in the higher resolution shell (69.7% instead of 40.2%) 
Table 2: Data collection statistics from individual crystals
Crystal 1 Crystal 2 Crystal 3
Source SLS/X06SA SLS/X06SA Diamond/I24
X-ray beam size 10 x 10 µm 40 x 100 µm 8x8 / 15x20 / 30x50 µm
“Wedges” collected (o) 0-30 / 40-60 / 70-90 0-25 0-10 / 10-50 / 60-100
Detector distance (mm) 300 520.0 535.9
Exposure time (s) 1 1 2
Rotation range/image (o) 1.0 0.25 1.0
Di"raction protocol Single wavelength Single wavelength Single wavelength
Wavelength (Å) 0.933 0.978 0.978
Detector CCD (Mar225) Pilatus 6M Pilatus 6M








No. of unique reflections 46204(3355) 30282(3567) 48210(3048)
No. of observed reflections 120917(6162) 42546(4112) 131664(3748)
Completeness (%) 80.5(40.2)[97.5] 52.9(43.2)[58.8] 86.8(38.6)[97.8]
Redundancy 2.6(1.8)[2.7] 1.4(1.2)[1.4] 2.7(1.2)[3.2]




Data-processing software MOSFLM/SCALA XDS/SCALA XDS/SCALA
Values for the outer shell are given in parentheses, and for around 3.2 Å resolution in square brackets (to appreciate 
the data completeness issues better).
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owing to the contribution of the 25o wedge contributed by the second crystal in the ‘face-on’ 
orientation. Although that region was collected for crystal 1 with the micro-beam, the ‘face-on’ 
images were di"racting at much lower resolution. 
This dataset was used for molecular replacement using as a search model a bacterial 
phosphodiesterase domain19, homologous to one of the four domains of ATX (with 28% identity). 
Although a clear solution was easily obtained in PHASER 20, our e"orts to refine this model and 
complete the structure were unsuccessful. The free R factor did not decrease and the electron density 
maps did not show any features for either the di"erences between the bacterial and mammalian 
sequences, or the three domains not present in the search model (~60% of the molecule). 
Therefore we focused our attention on obtaining a Se-Met dataset, a quest that failed. This 
e"ort was hampered by lack of enough Se-Met protein required for obtaining large enough 
native crystals. Crystals did not exceed 1 µm in thickness, and the other two plate dimensions were 
typically less than 40 µm. We were thus unable to allow collection of a redundant and high quality 
dataset, even to a modest resolution of about ~3.5 Å. Minimizing exposure to increase lifetime led 
to data that were too weak. While the SAD data we were able to collect from a few small crystals 
were of reasonable quality, the redundancy was too low (anomalous redundancy 3.7 for our best 
dataset) to generate a good enough anomalous signal to noise ratio (anomalous correlation 
dropped below 30% at ~7Å resolution for the best data). Attempts to combine datasets from 
di"erent crystals did not produce a better anomalous signal to noise ratio. Soaking experiments 
proved physically di#cult to perform due to the small crystal size and did not result in usable data.
Data collection at the Diamond I24 microfocus beamline using variable beam size
During our attempts to obtain a Se-Met crystal from nano-drops for di"raction studies, we 
produced native crystals with some alterations in the crystallization protocol (Table 1). The 
Fig. 2: Setup for di!raction data collection (with the beam shown in green and the crystal in yellow) and 
the corresponding sample di"raction images illustrating the di"erences in (A) ‘edge-on’; and (B) ‘face-on’ 
orientations. The size of the beam and crystal in the diagram are approximate.
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size of these crystals was similar to that of the previous crystals, despite being grown from 
nano-drops, and they were used to test data collection protocols for subsequent Se-Met 
data collection at I24, a tuneable microfocus beamline that was at the time in late stages of 
commissioning at Diamond Light Source. I24’s versatile optical design (Evans et al., 2006) 
allowed the use of three beam sizes, a micro-beam of 8%8 microns, a medium-size beam of 
15x20 microns and a larger 30x50 micron beam (v%h). As changes in beamsize were achieved 
via the refocusing of mirrors rather than through the use of apertures or defining slits, the total 
flux at the sample position of ~1012 ph/s is preserved for each of these di"erent sized beams. I24 
was designed specifically to allow matching of X-ray beam properties to sample properties and 
in the simplest case this means that, where possible, the beam size is matched to the projected 
dimensions of the crystal along the beam axis. 
For these crystals the beamsize was adjusted accordingly for di"erent crystal orientations and 
this allowed a dataset of good quality and completeness to be collected from a single micro-crystal.
DISCUSSION
Protein production in stably transfected mammalian cells for crystallographic 
studies 
We have expressed a mammalian glycoprotein in stably transfected HEK-293 cells. Producing 
a stable cell line with the Flip-in system is straightforward, and allows routine production of 
protein without the need for transfection, minimizing the routine costs (the cost of large DNA 
preparations for transfection of large volumes of cell culture as well as the cost of transfection 
media are eliminated), as well as the uncertainty and heterogeneity of transfection success. 
Production in roller bottles allows straightforward scale-up of the procedure, at a low cost 
since the use of FCS is eliminated in final stages. Loading of the medium containing the 
secreted protein in a fast flow resin, allowed much faster protein purification without prior 
concentration. Additionally, screening commercial products to find a device that allowed 
centrifugal protein concentration, was important to be able to concentrate the protein further, 
faster and in smaller volumes, and enabled more e#cient crystallization screening. Finally, we 
were able to use nano-crystallization vapour di"usion experiments in 0.3 µl drops, yielding 
Table 3: Data collection statistics for the combined dataset
Crystal 1+2
Source SLS/X06SA
Resolution range (Å) 50.0-2.6 (2.74-2.6) [3.36-3.11]
No. of unique reflections 52092(5747)
No. of observed reflections 162655(10544)
Completeness (%) 91.0 (69.7) [99.0]
Redundancy 3.1 (1.8) [3.4]





Values for the outer shell are given in parentheses.
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excellent quality small crystals, similar to these obtained in 10 µl drops. This is another case in 
the largely anecdotal line of evidence that argues that drop size does not correlate well with 
crystal size and quality.
Limitations of using micron-thick plate-like crystals 
Crystallization screening using the vapour di"usion method in nano-drops allowed the 
production of very small plate-like crystals. Subsequent optimization in very large drops (10 µl 
total) in the presence of detergent, or later also in nano-drops (0.3 µl), allowed the formation of 
micron-thick crystals that were suitable for collecting 2.6 Å resolution di"raction data.
Despite recent excellent advances in instrumentation, the manipulation of very thin plate 
crystals presents clear challenges that need to be resolved. Since plates have a preferred orientation 
in mounting loops, they are invisible in ‘edge-on’ orientation, calling for grid-scan procedures21-23 
such as the one available in I24, to determine the ideal centring by di"raction in that orientation.
Furthermore, while a micro-beam is ideal for collecting data at the ‘edge-on’ orientation, 
a larger size beam is preferable ‘face-on’, as illustrated in Figure 3. As an example consider two 
possible beam sizes, a micro-beam of 10x10 µm, and a more common beamsize of 100x50 µm, 
being used to measure data from a typical rATX crystal of 100x50x1 µm. Clearly neither situation 
is optimal. In the ‘edge-on’ orientation, a micro-beam is best, Figure 3A. With such a thin 
crystal, in the ‘edge-on’ orientation the maximal volume is exposed: for the sizes above, at that 
orientation a volume of ~500 µm3 is exposed (1 µm of crystal thickness x 10 µm of crystal along 
the long axis across the beam, which is limited by the beam size, x 50 µm of the crystal’s other 
long axis along the beam). At the ‘face-on’ orientation, only ~100 µm3 of crystal volume would 
be exposed to the micro-beam, Figure 3B (1 µm of crystal thickness x 10 µm x 10 µm of crystal 
limited by the beam size in both long crystal directions). However, after a few degrees rotation, 
one can a"ord a larger beam, and finally in the ‘face-on’ orientation, a large beam matching 
the plate size is best suited, Figure 3D (1 µm of crystal thickness x 100 µm x 50 µm of crystal 
along the long axes across the beam) and would result in ~5,000 µm3 of crystal being exposed. 
However, the large beam would result in a too high background in the edge-on orientation, 
as e"ectively only 2% of the beam would hit the crystal, Figure 3C. In our opinion, variable 
beam sizes where the beam size adapts dynamically during data collection could have possibly 
improved data collection on these crystals.
The availability of a variable beam size at I24 allowed data collection from a single plate crystal 
even though only three discrete sizes were o"ered at the time. The data obtained using the 
grid-scan technique to centre the edge-on orientation and the subsequent use of variable beam 
sizes resulted in data being measured from a single crystal of a quality comparable to that obtained 
from two crystals at the SLS X06SA beamline using two di"erent micro-di"ractometers. At the 
time of these experiments only three discrete beam sizes were available at I24 but the design goal 
for this beamline is continuous, independent, variability of beamsize in both directions so as to 
permit optimal adaptation of beam characteristics to the size and orientation of the sample.
We argue here that an X-ray beam that could be changed in size every few degrees 
throughout a data collection or software that would allow three-dimensional data collection 
strategies utilizing all the volume of thin plate crystals, a micro-beam, and varying exposure 
times to account for crystal volume changes, allows more e#cient data collection. If the 
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available beam size matches the smallest crystal dimension, micro-crystals, in a way, present 
the lesser challenge for data collection: the choice is limited to a single volume. Needle-like 
crystals provide an additional dimension of complexity: to utilize the whole crystal volume a 
one-dimensional ‘scan’ across the length of the needle is desirable24, using a fixed beam size. 
Plate-like crystals however create a more complex challenge: to utilize the crystal volume 
e#ciently, two-dimensional scanning would be needed, along with variation of the beam size 
dependent on crystal orientation. Such procedures could have maybe allowed data collection 
from a single Se-Met crystal of rATX, which might in turn have enabled to record the anomalous 
signals more accurately, to facilitate structure solution. In retrospect, the main obstacle to 
structure solution from these data was in fact the size of the crystals rather than the di"raction 
limit or other basic problems. 
Determination of the crystal structure of rATX was made possible by the addition of two 
components in the precipitating solution of our ‘basic’ crystallization protocol, and is described 
separately in the paper by Day et al (submitted for publication). 
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Fig. 3: A schematic diagram illustrating benefits and problems of small and large beams (shown in 
green) for plate-like crystals (shown in yellow): (A) thin plate edge-on with micro-beam (good); (B) thin 
plate face-on with micro-beam (bad); (C) thin plate edge-on with large beam (bad); and (D) think plate 
face-on with large beam (good).
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ABSTRACT
Autotaxin (ATX) or ecto-nucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) is 
a secreted lysophospholipase D that generates the lipid mediator lysophosphatidic acid (LPA), 
a mitogen and chemoattractant for many cell types. ATX-LPA signaling has roles in various 
pathologies including tumour progression and inflammation. However, the molecular basis 
of substrate recognition and catalysis, and the mechanism of interaction with target cells, 
has been elusive. Here we present the crystal structure of ATX, alone and in complex with 
a small-molecule inhibitor. We identify a hydrophobic lipid-binding pocket and map key 
residues required for catalysis and selection between nucleotide and phospholipid substrates. 
We show that ATX interacts with cell-surface integrins via its N-terminal somatomedin-B-
like domains, using an atypical mechanism. Our results define determinants of substrate 
discrimination by the ENPP family, suggest how ATX promotes localized LPA signaling, and 
enable new approaches to target ATX with small-molecule therapeutics. 
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INTRODUCTION
Autotaxin (ATX), also known as ecto-nucleotide pyrophosphatase/phosphodiesterase 2 
(ENPP2), is a secreted glycoprotein2 that acts as a lysophospholipase D (lysoPLD), converting 
lysophosphatidylcholine (LPC) into the lipid mediator lysophosphatidic acid (LPA)3,4. LPA acts on 
specific G protein-coupled receptors eliciting responses ranging from chemotaxis and neurite 
remodelling to cell proliferation and survival5,6. The ATX-LPA signalling axis is implicated in vascular 
and neural development7-10, tumour progression and metastasis11-16, as well as inflammation17, 
fibrotic disease18,19 and neuropathic pain20. As such, ATX holds promise as an attractive and easily 
accessible therapeutic target. We and others have recently described potent small-molecule 
inhibitors of ATX that are capable of lowering LPA levels in the circulation21,22.
ATX is a ~100 kDa glycoprotein that has several distinct domains (Fig. 1a). At the N-terminus 
it harbours two consecutive cysteine-rich somatomedin-B-like (SMB) domains, a fold known to 
be involved in protein-protein interactions23. The ATX SMB domains are attractive candidates 
for mediating the demonstrated binding of ATX to activated platelets and lymphocytes in an 
integrin-dependent manner17,24, thereby providing a possible route for localized LPA production 
and signalling at sites of injury and inflammation. The central catalytic phosphodiesterase (PDE) 
domain follows the SMB domains. It is similar to the catalytic domain of alkaline phosphatases, and 
its closest homologue with a known structure is a well-characterised bacterial phosphodiesterase1. 
Finally, at its C-terminus, ATX contains a nuclease-like (NUC) domain, which is catalytically inert 
and has been suggested to be involved in substrate binding and presentation25. 
ATX/ENPP2 is one of seven mammalian ENPP type ectophosphodiesterases26, containing 
central PDE domains. Due to lack of structural data, the molecular basis for the diverse substrate 
preferences of ENPP family enzymes is not well understood. For example, the phosphodiesterase 
activity of the founding member ENPP1, a protein that has been implicated in the aetiology of 
mineralisation diseases and diabetes, is nucleotide-selective, whereas ATX/ENPP2 preferentially 
hydrolyzes lysophospholipids although it also accepts nucleotides as substrates. 
The most potent small-molecule inhibitor we have recently described22 contains 
a boronic acid, designed to specifically bind to the catalytic threonine of ATX. A structure-
based mechanistic understanding of how boron binds to the threonyl nucleophile, and of the 
details of substrate recognition and catalysis by ATX will accelerate the further development of 
selective ATX inhibitors.
To understand how the domains of ATX are organized, their role in determining selectivity 
for lipid over nucleotide substrates, how our boronic acid inhibitors interact with ATX, and 
how the integrin-mediated interaction with platelets takes place, we determined the crystal 
structure of ATX/ENPP2; in this paper we present the structure of ATX from rat (rATX) and the 
structure-based biochemical analysis of human ATX (hATX). 
MATERIAL AND METHODS
Protein production, crystallization and di!raction data collection 
All protocols are described in references27,28. The HA155 inhibitor was mixed in three-molar 
excess with rATX and co-crystallized in conditions similar to the native data form27.
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Fig. 1: Sequence alignment and secondary structure elements. Sequence alignment of rat and human 
ATX/ENPP2, human ENPP1 and the bacterial phosphodiesterase XaNPP. The secondary structure&elements 
from the ATX structure are marked on top of the alignment,&and these of XaNPP in the bottom. The ATX 
specific deletion is marked in magenta.
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Structure solution and refinement
Crystallographic statistics are shown in Table 1. Structure solution was performed using 
PHASER29 in the hybrid molecular replacement - single anomalous dispersion mode. We used 
the structure of XaNPP (2GSN1) as a search model, with non-conserved side chains truncated 
to the last common atom between residues. A clear rotation function solution was obtained 
(Z-score 15.01), su#cient to orient the single molecule of the asymmetric unit in the P1 space 
group. Using the phase probability distribution from that solution, PHASER identified ten 
heavy atom sites, using the anomalous di"erences from the zinc and iodine ions, resulting in 
phases with a figure of merit of 0.4. Solvent flattening followed by automated model building 
with ARP/wARP30 resulted in 737 residues distributed in 8 chains. The model was completed 
manually using COOT31, interspersed with reciprocal space refinement cycles in REFMAC532. The 
final model was validated using the MolProbity33 server, and is of excellent quality without any 
Ramachandran outliers, ranking in the 93rd best percentile of PDB structures in that resolution. 
The second native crystal form, without Iodine in the crystallization conditions, was solved by 
Table 1: Data collection and refinement statistics 
Native + I Native 2 HA155 Inhibitor
Data collection













    a, b, c (Å) 53.8, 63.3, 70.5 95.3, 121.8, 158.4 63.99, 90.2, 152.7
    !,'", #'(") 98.8, 106.2, 99.8 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution (Å) 20.0-2.05 (2.12-2.05) 20.0-2.6 (2.74-2.6) 20.0-3.2 (3.36-3.2)
R
merge
0.097 (0.378) 0.191 (0.488) 0.128 (0.571)
I / &(I) 13.9 (2.5) 7.7 (1.5) 10.3 (3.5)
Completeness (%) 96.8 (93.9) 91.9 (69.7) 98.5 (98.5)
Redundancy 4.8(3.0) 3.1 (1.8) 6.0 (5.6)
Refinement
Resolution (Å) 20.0-2.05 20.0-2.6 20.0-3.2





17.2 / 22.0 21.6 / 27.5 20.1 / 25.5
No. atoms
    Protein 6396 12333 6140
    Ligand/Ion/Glycan 5/3/39 -/6/56 34/3/39
    Water/Iodine 332/28 19/- 11/6
B-factors
    Protein 38 29 53
    Ligand/ion/Glycan 34/35/42 -/30/27 40/40/56
    Water/Iodine 24/51 6/- 23/9
R.m.s. deviations
    Bond lengths (Å) 0.017 0.013 0.008
    Bond angles (") 1.62 1.52 0.93
* For the ‘Native + I’ and ‘HA155 Inhibitor’ datasets a single crystal was sued. For the ‘Native 2’ dataset two crystals 
were used.
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molecular replacement and refined; apart from minor di"erences in disordered regions the 
two models are identical. The HA155 complex was determined by molecular replacement using 
the native ATX model without ions; the di"erence map showed clear density for the omitted 
zinc ions and the HA155 ligand. This structure was refined with autoBUSTER34. After adjusting 
protein regions, HA155 was modeled and refined using a dictionary generated by PRODRG35 and 
manually adjusted to conform to the tetrahedral geometry expected for the reversibly covalent 
bound boron atom. Validation with Molprobity shows 96.2% of all residues in Ramachandran 
favored regions, ranking in the 100th
 
percentile for that resolution. 
Structure analysis 
Structural similarity searches were performed with SSM36 using default parameters. All interface 
calculations were performed with PISA37. The reported interface area is the di"erence in the 
accessible surface of isolated and interacting structures divided by two. 
The HADDOCK web server was used38 for docking a flexible LPC molecule into the structure 
of rATX. The phosphate atom was restrained to a position consistent with the observed 
phosphate in the AMP:XaNPP complex. The binding pocket residues that were in contact with 
the HA155 inhibitor were treated as ‘active’ residues that make contacts with the LPC substrate. 
All other parameters were used with default values. Docking experiment resulted to a single 
cluster of 200 structures.
Site directed mutagenesis 
All constructs were made using standard molecular biology procedures and verified by 
sequencing.
Protein production for EF-hand mutants 
Cells were transiently transfected at 30-40% confluency using Fugene. The medium was 
collected 72 h later and the cells were lysed in 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1% (w/v) 
Triton X-100 supplemented with 0.5 mM PMSF and 0.5 mM benzamide. After three freeze-
thaw-cycles and ultracentrifugation (30 min at 100,000g) the supernatant was collected and 
used as ‘cell lysate’ in Western blots and to determine NPP2 activity.
Protein production for binding site mutants 
HEK293 cells were transiently transfected at 30-40% confluency using Fugene-6. The medium 
was collected 96 h later and used for pNP-TMP assays and LPC assays. Protein levels were 
quantified by Western blot.
ATX/lysoPLD activity assay 
ATX lysoPLD activity was measured by the release of choline from LPC22. Briefly, medium 
from transfected HEK293 cells containing approximately 5 nM hATX (quantified by Western 
blot analysis using purified wild-type ATX as a standard), was incubated with 500 µM LPC 
species in Tris-HCl buffer (pH 7.4), 0.01% (w/v) Triton X-100 for 4 h at 37 C. Liberated choline 
was detected colorimetrically using choline oxidase (1 Unit mL-1), horseradish peroxidase 





320/450nm in 96-well plates.
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Nucleotide phosphodiesterase assay 
ATX nucleotide phosphodiesterase activity was measured colorimetrically using the nucleotide 
derivative pNP-TMP (p-nitrophenyl thymidine 5´-monophosphate) as a substrate39. 15 nM hATX 
of the preparations used also for the lysoPLD assay above, was incubated with 1 mM pNP-TMP in 
glycine-bu"ered saline at pH 9.5 in 96-well plates. The amount of liberated para-nitrophenolate 
(pNP) was determined by the absorbance at 405 nm for 3 h. For investigations of LPA inhibition, 
incubations contained 0.01% (w/v) Triton X-100 and varying concentrations of LPA (18:1).
Protein production for platelet binding assays and LPA inhibition experiments
ATX proteins were generated by expression in CHO cells using variants of pSecTag engineered to 
fuse an IgK leader sequence and furin protease site N-terminal of a His6 sequence. Secreted proteins 
were purified from conditioned medium and concentrated to ~1 mg ml -1 for use in binding assays.
Static platelet adhesion assays 
The interaction of ATX to activated platelets was studied by measuring binding of calcein labeled 
platelets to fibrinogen, ATX or fragments using a microtiter plate assay as described previously24. 
In brief, human platelets were isolated from citrate anticoagulated blood. Platelets were labeled 
by incubation with 7 mM calcein-AM and 150 nM PGI2 and then isolated by gel filtration using 
Sepharose 2B eluted with Tyrodes bu"er (12 mM NaHCO
3
, 138 mM NaCl, 5.5 mM glucose, 2.9 mM 
KCl, 10 mM HEPES, 0.35% (w/v) fatty-acid-free BSA, pH 7.35). ATX, ATX fragments or fibrinogen 
were diluted in 50 mM Tris pH 7.4 100 mM NaCl and incubated in a Microfluor 96-well plate for 
16 h at 4o C. The wells were washed and blocked by incubation with Tyrodes bu"er for 1 h at 
RT. Gel filtered platelets were diluted 200 times in Tyrodes bu"er containing 2 mM CaCl
2
, 1 mM 
MgCl
2
 and platelet activators, small molecule inhibitors or blocking antibodies. After incubation 
for 60 min at RT, wells were washed with Tyrodes bu"er containing 2 mM CaCl
2
, 1 mM MgCl
2
 and 
bound platelets were quantified by measurement of calcein fluorescence.
RESULTS
The crystal structure of Autotaxin
We determined the crystal structure of the full-length secreted form of rat ATX (rATX), which 
is 93% identical to the human enzyme hATX (Fig.1). A variant of rATX, in which two of the three 
glycosylation sites were mutated, leaving the single site needed for activity40, was produced in 
HEK293 cells, purified and crystallized27,28. The structure was determined to 2.0 Å resolution by a 
combination of molecular replacement and single-wavelength anomalous dispersion (Table 1). 
rATX presents a compact and robust architecture for a multi-domain protein (Fig. 2a); two 
di"erently packed crystal forms show virtually identical domain placement (Fig. 2b,c). The two 
N-terminal cysteine-rich somatomedin-B-like (SMB) domains and the C-terminal nuclease-like 
(NUC) domain contact opposing sides of the catalytic phosphodiesterase (PDE) domain. 
The structures of the individual domains of rATX (Fig. 2a) all resemble known folds (Fig. 3). 
The N-terminal SMB domains are structurally similar to both the SMB domain of vitronectin23 
and that of ENPP1 (PDB:2YS0, unpublished) (Fig. 3a). The catalytic PDE domain is most similar 
to the Xanthomonas axonopodis nucleotide pyrophosphatase1 (XaNPP) (Fig. 3b). The catalytic 
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Fig. 2: The structure of ATX. (a) A schematic view of the domain structure of ATX; (b) Cartoon 
representation with the SMB domains coloured in pink and magenta, the PDE domain in green, the NUC 
domain in blue, the lasso loop wrapping around the NUC domain in orange (the lasso loop interacts 
with the rest of the proteins through 18 hydrogen bonds, 8 salt bridges, and a disulphide bond between 
residues 566 and 666) and the short loop connecting the SMB domains to the PDE domain in cyan; the 
phosphate and the zinc ions bound to the active site as well as cystine bridges are shown in stick-and-
sphere representation, with the S# atoms in yellow, phosphorous in orange, zinc in pink; (c) The same 
cartoon as above in a di"erent orientation, showing the active site with the bound phosphate and zinc ions 
and the lasso loop wrapping around the NUC domain to the left; the colored boxes relate to panels (d,e,f) 
showing the interface between the PDE and NUC domains; (d) The essential Cys-bridge that connects the 
PDE and NUC domains. (e) The essential glycan chain; (f) the C-terminal helix highlighted in lemon-green, 
with the important Lys-852 and its two salt-bridge partners, Glu-830 and Asp-836. All structural figures 
were created with Pymol (http://www.pymol.org).
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residues of ATX and XaNPP, including the catalytic Thr209 and Thr90 respectively, are also 
well conserved (Fig. 3a). The closest structural match to the C-terminal NUC domain is the 
cyanobacterial nuclease NucA41 (Fig. 3c), but none of the catalytic residues in NucA is conserved 
in the ATX NUC domain, accounting for its previously observed catalytic inactivity.
The PDE-NUC domain interface
The PDE and NUC domains are tethered together in a strikingly rigid manner. The interface 
area is 1280 Å2, reinforced by seven hydrogen bonds and nine salt bridges. Many elements of 
the PDE domain participate in this interaction, while only the C-terminal region (802-859) of 
the NUC domain is involved. The two domains are tethered by an intermolecular Cys-bridge 
between residues 413 and 805 (Fig. 2d) that is essential for retaining catalytic activity25. Moreover, 
a large ‘lasso’ loop of 50 residues (540-589), starting at the end of the PDE domain, wraps tightly 
around the NUC domain (Fig. 2c), finally entering the fold from the side opposite to the PDE 
Fig. 3: ATX domains and closest structural homologues. (a) The two SMB domains of ATX/ENPP2, the ENPP 
SMB1 domain (PDB:2YS0, unpublished), and two structures of the vitronectin SMB domain (PDB:1OC042, 
3BT143) are shown side by side, colored blue to magenta from N to C terminus with cystine bridges shown 
as sticks, with the S# atom atoms in yellow. The ATX SMB domains share 38% sequence identity with the 
SMB domain of vitronectin, and 56% with that of ENPP1, displaying in both cases an rmsd of about 1.3 Å over 
40 superposed C!s; (b) The ATX and XaNPP phosphodiesterase (PDB:2GSN1) domains shown in matched 
orientations; the short loop (residues 274-280) that is more extended in XaNPP (residues 154-178) is shown 
thicker and in ruby and the bound zinc ions are shown as grey spheres; the sequence identity between the 
two is 32%, with 1.5 Å rmsd over 335 superposed C!s; (c) Side by side comparison of the ATX nuclease domain 
with&the A.sp nuclease (PDB:1ZM841); the sequence identity is 19%, with 2.1 Å rmsd over 335 superposed C!s. 
The EF-hand-like calcium (brown sphere) binding motif is at the bottom left and is absent in the bacterial 
nuclease; the A.sp ion binding sites are indicated with&magenta spheres and are absent in the ATX domain.
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domain. Furthermore, the first two N-acetyl-glucosamine moieties of the essential Asn-524-linked 
glycan chain40 are packed between the PDE and NUC domains (Fig. 2e), forming an interface area 
of 321 Å2. Finally, the C-terminal region from residues 829-850, which is essential for secretion25, as 
well as Lys852, which is required for catalytic activity25, are also in the domain interface (Fig. 2f). In 
the structure, Lys852 makes two salt bridges with Glu830 and Asp836 and is presumably important 
for positioning the C-terminal helix. It thus appears that evolution has selected for an extended 
range of interactions that bind the catalytically dead NUC domain to the active PDE domain.
The NUC domain of ATX (and ENPP1 and ENPP3) encompasses an EF-hand-like (EFL) motif26 
(739DYNYDGLRDTEDE751), crucial for activity for ENPP1 and ENPP344, but reportedly not for ENPP245. 
This 13-residue EFL motif binds Ca+2 (Fig. 4a), but is not flanked by helices. Notably, its first residue, 
Asp739, bridges to Lys430 and is the only residue outside the C-terminus of the NUC domain that 
interacts with the PDE domain (Fig. 4b). ATX mutated at this site (K430A) was as active as the 
wild-type enzyme, but a significant amount was retained intracellularly (Fig. 4d). Furthermore, the 
secreted fraction of ATX (K430A) was more sensitive to thermal denaturation than wild-type ATX 
(Fig. 4e), suggesting that the salt bridge between Lys430 and Asp739 contributes to stabilization 
of the PDE-NUC interface. Mutation of three residues of the EFL motif (D739S/N741A/D743S) 
abolished secretion of ATX (Fig. 4d). The mutant proteins that accumulated intracellularly showed 
strongly reduced activity (Fig.4e), consistent with previous findings for ENPP1 and ENPP344. 
The phosphodiesterase catalytic site 
The PDE domains of ATX and XaNPP1 share similar architectures with fully conserved catalytic 
residues (Fig. 5a,b). At the active site, the Zn+2 atom proximal to the catalytic Thr209 (Thr210 in 
hATX) is coordinated by the side chains of two aspartates and one histidine (Asp171, Asp358, His359), 
whereas the distal zinc is coordinated by one aspartate and two histidines (Asp311, His315, His474). 
An asparagine residue (Asn230; Asn 231 in hATX) faces the two metal ions in a position similar 
to that of Asn111 in XaNPP. Asn111 was shown in XaNPP not only to be important for catalysis 
but also to confer specificity for phosphodiester bond hydrolysis1; an arginine substitution at 
this position favoured phosphatase activity. In hATX, the N231A mutation significantly impairs 
the catalytic activity against both phospholipid and nucleotide substrates (Fig. 7a,b). Since ATX 
hydrolyzes ATP to generate AMP and pyrophosphate rather than ADP and phosphate, Asn230 is 
likely responsible for this preference for diester against monoester hydrolysis. 
In one of the ATX crystal forms we located a phosphate ion (Fig. 3a and Fig. 6a) that 
matches the positions occupied in XaNPP complex structures by the !-phosphate of AMP, or 
the transition state analogue vanadate (Fig. 5b). These similarities suggest a conserved catalytic 
mechanism, in which the activated O# nucleophile of Thr209 attacks the phosphate group of 
a substrate, resulting in the formation of a transition state involving a phosphate ester linkage1. 
The intermediate can then be hydrolyzed to the products, i.e. LPA or AMP.
The substrate and inhibitor binding pocket
ATX hydrolyzes both nucleotide and phospholipid substrates, at least in vitro. The location of 
the nucleotide binding site in ATX can be inferred from the structure of XaNPP bound to AMP 
(Fig. 5f). The shape of this site remains fully conserved in ATX (Fig. 5e). These two enzymes, and 
other ENPP family members, are therefore expected to bind nucleotides in a similar manner.
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Fig. 4: The EF-hand-like motif. (a) The bound ion has structural and chemical characteristics consistent 
with Ca+2 (typical coordination sphere and absence of anomalous density); the coordinating residues 
are shown, together with the coordination distances. (b) The EF-hand-like motif contact with the 
phosphodiesterase domain is mediated by the salt bridge between Asp739 and Lys430. (c) The canonical 
EF-hand motif positions and most commonly identified residues, aligned to the ATX EF-hand-like motif. 
The residues in positions 1,3,5,9 (or X,Y,Z,-X; S.F.3C) are typical (Asp, Asn, Asp, Asp); and the position 7 
ligand (-Y) is provided by the expected carbonyl of a hydrophobic Leu, uncommon for that position, but 
usually present at position 8, which in ATX is a very unusual Arg. The typical Gly is also conserved in position 
6. However, the bidentate binder at position 12 (-Z, typically Asp or Glu), although an Asp in sequence, 
is not participating in ion binding; the -Z position ligand is instead provided by a water molecule fixed 
by the Glu residue in position 13 of this motif. (d) Expression of wtATX and K430A mutant and the triple 
EF-hand-like mutant in cell lysates and the culture medium (upper panels). Also shown is the specific 
lysophospholipase D activity, as compared to that of wtATX, of the secreted fraction for the K430A mutant 
and the intracellular fraction of the EF-hand-like mutant. (e) Activity of wtATX and K430A mutant after 
thermal denaturation at various temperatures, and as function of the pre-incubation time in various 
temperatures, indicating that the stability of the K430A mutant is compromised.
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ATX-mediated LPC hydrolysis is specifically and potently inhibited by a series of small-
molecule boronic acid inhibitors that lower plasma LPA levels in mice following intravenous 
administration22. We determined a structure of rATX in complex with one of these inhibitors, 
HA15546 (Fig. 5c and Fig.6b,c, Table 1), which enables us to correlate the activity of this inhibitor 
with its binding mode and make inferences about lipid substrate binding. The boron atom 
on one end of the inhibitor forms a reversible covalent bond with the nucleophile hydroxyl 
group of Thr209. One of the two boron hydroxyl groups is further stabilized between the 
two zinc ions. A search of the protein data bank did not yield any other structures in which a 
borate moiety is similarly complexed by two zinc ions and a threonyl nucleophile47. The rest 
of the hydrophobic four-ring system of HA155 forms an extended network of van der Waals 
contacts, with an interaction interface of 574 Å2. The first two aromatic rings of HA155 assume 
positions similar to those of the ribose and the adenine in the structure of XaNPP bound to 
AMP (Fig. 5c,e). The third, thiazolidinedione, ring would not be accommodated by the XaNPP 
structure (Fig. 5d). The last aromatic ring, a hydrophobic fluoro-benzene, is pointing directly 
into a deep hydrophobic pocket, oriented perpendicular to the protein surface.
We hypothesize that this hydrophobic pocket also binds the acyl chain of lysophospholipid 
substrates. We used High Ambiguity Driven DOCKing (HADDOCK38) to create a model of the 
binding of LPC(14:0) to our structure of rATX. Fig. 5g and h show how the acyl chain can be 
easily accommodated in this pocket. The model also demonstrates that the pocket is large 
enough to accommodate only a single aliphatic chain, and explains how ATX sterically excludes 
di-acyl phospholipids. It is noteworthy that our model is consistent with previously reported 
biochemical data: for example, the change of Leu213 (Leu214 in hATX), one of the hydrophobic 
residues lining the pocket and contacting the modeled substrate, to a polar histidine has been 
shown to decrease LPC hydrolysis48. 
To validate our model further, we constructed additional binding site mutants and 
examined their activity. These mutagenesis studies employed hATX (residue numbers in the 
human enzyme are n+1 compared to the rat enzyme above, owing to a single residue insertion 
after residue 37). hATX and catalytically inactive hATX T210A were used as controls to evaluate 
activity of the hydrophobic binding pocket mutants: F211A, Y307Q, L214H, F275Q, A305E, F274E, 
A218V, S170E (Fig. 7a). All mutants were expressed at levels similar to the wild-type enzyme. 
They were quantified and assayed in an LPC hydrolysis assay using saturating concentrations 
of LPC(14:0), the optimal substrate in vitro (Fig. 7c). All of these hydrophobic pocket mutants 
showed reduced lysoPLD activity levels when compared to wild-type hATX (Fig. 7b).
The A218V mutant, which has about half the activity of hATX, targets a residue deep in the 
hydrophobic pocket and alters LPC selectivity (Fig. 7a). This mutant hydrolyzes short-chain LPCs 
more e#ciently than the wild-type protein (Fig. 7c). This can be explained by the presence of 
a bulkier valine residue at the bottom of the pocket, which possibly mediates a better contact 
with e.g. LPC(12:0), but excludes substrates with longer acyl chains. A218V and similar mutations 
that alter the acyl chain length selectivity could provide useful tools for probing the biological 
role and significance of ATX in generating distinct molecular species of LPA.
Many of the binding cleft variants di"erentially a"ect LPC and nucleotide hydrolysis. 
Although all of them are less active in the LPC hydrolysis assay, some can still hydrolyze nucleotide 
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Fig. 5: The ATX catalytic site and substrate binding pocket. (a) The active site of ATX and (b) of XaNPP 
(PDB: 2GSO1). Side chains atoms are shown as sticks, with the C
a
 atoms as spheres; all oxygen and nitrogen 
atoms are in red and blue respectively; Zn+2 ions are grey spheres; phosphate atoms are coloured orange; 
and vanadium atoms magenta; (c) A surface representation of the ATX binding site with the HA155 inhibitor 
buried in the binding pocket and shown as sticks with carbon atoms colored grey and the covalently 
bound boron pink; the ATX surface is green with the short loop that is more extended in XaNPP and ENPP1 
(residues 274-280) colored ruby; (d) The surface of XaNPP coloured in aquamarine, superposed on the ATX 
complex with HA155; the extended XaNPP- and ENPP1-specific loop (residues 154-178) in ruby, highlighting 
the absence of the hydrophobic pocket in XaNPP; (e) The ATX substrate binding site shown as in (c) but 
with AMP superposed from the XaNPP complex structure; (f) The XaNPP surface with bound AMP (PDB: 
2GSU1) shown as sticks; (g) The ATX surface colored by electrostatic potential (-70 to 70 kT) to highlight 
the hydrophobic nature of the binding pocket, is shown together with a stick model of a docked LPC 
molecule; (h) A view similar to (g) colored as in (c),(e) and with the second SMB domain in magenta, 
highlighting the close interaction of the SMB domain with the lipid binding groove. The narrow tunnel is 
visible as a white hole in the middle.
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substrates with near wild-type activity. These include the previously reported L214H mutant and 
the novel mutants S170E, A218V and A305E (Fig. 7b), which target the acyl chain lipid binding 
region of the pocket. In contrast, the Y307Q or F211Y mutants, which target the region of the 
binding site that accommodates both nucleotides and lipids, are significantly less active against 
both lipid and nucleotide substrates. In fact, these two variants are comparatively less active 
against nucleotides than lipids, possibly because these mutations have a greater e"ect on the 
bulkier nucleoside moiety than the glycerol group of the lipid substrates. These observations 
suggest that the hydrophobic binding pocket is an extension of the nucleotide binding site that 
specifically accommodate lysophospholipid acyl chains, without a"ecting nucleotide binding. 
When the structures of ATX and XaNPP are superimposed, a stretch of 18 amino acids in 
XaNPP occupies the space corresponding to the hydrophobic binding pocket of ATX. This 
stretch of amino acids in XaNPP thus precludes it from accommodating lysophospholipids 
(Fig. 3b). Sequence alignments indicate that while ATX has a deletion in this region, XaNPP and 
ENPP1 do not (Fig. 1). The presence of this stretch of amino acids in ENPP1 and XaNPP therefore 
explains why they cannot hydrolyze lysophospholipids, and why ENPP1 is insensitive to ATX 
inhibitors such as HA15522. 
Fig. 6: Electron density maps for bound PO4 for HA155 and chemical structure of HA155. (a) Stereo 
pair of the 2mFo-Dfc &Fourier synthesis contoured at 1.2 rms of the 2.1 Å map, showing the &density for 
the active site residue, the Zn ions and the bond PO4. (b) Stereo pair of the bias-removed composite 
omit map at 3.2 Å, showing the bound ligand and the covalent linkage to Thr209. (c) Chemical structure 
of the HA155 inhibitor.
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The SMB domains and interaction with integrins 
The two N-terminal Cys-rich SMB domains in ATX (atxSMB1 and atxSMB2) provide the first 
structural instances of these domains in the context of an intact protein. The structure of the 
SMB domain of the plasma protein vitronectin (vSMB) is known, both alone and in complex with 
the plasminogen activator inhibitor-142 (PAI-1, Fig. 10a) and the urokinase-type plasminogen 
activator43 (uPAR) (Fig. 10b). The structural organization of the SMB domain cysteine knot fold, 
comprising four pairs of crossed disulfide bonds, had been the subject of considerable debate23,49. 
Fig. 7: Biochemical analysis of human ATX and mutants. (a) A simplified drawing of the ATX binding 
pocket. The residues used for mutagenesis studies are indicated; (b) Modulation of LPC and pNP-TMP 
hydrolysis activity by ATX mutants, indicating the importance of specific residues for selectivity in LPC and 
nucleotide hydrolysis; (c) The A218V mutants prefers shorter chain lengths; the activity for WT hATX and 
A218V mutant was normalized to 100% for LPC(14:0); (d) LPA(18:1) inhibition of nucleotide hydrolysis for 
wild-type ATX and #SMB-ATX. All error bars represent the s.e.m.
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The organization of the atxSMB domains is consistent with the vitronectin SMB X-ray and NMR 
structures, as well as with the NMR structure of the ENPP1 SMB domain (PDB:2YS0, unpublished).
Both atxSMB domains form extensive interactions with the catalytic PDE domain (Fig. 10c,d). 
The interaction between the atxSMB1 domain and the PDE domain involves approximately the 
same surface that mediates the vSMB to PAI-1 and uPAR interactions. However, atxSMB2 uses an 
unusual interface for interaction with the PDE domain, leaving the surface more typically used 
for protein-protein interactions available to engage with other binding partners (Fig. 10d). We 
examined whether hATX can interact with PAI-1 by co-expression and immuno-precipitation 
experiments, but detected no interaction (Fig. 7). 
Fig. 8: ATX does not bind to PAI-1. (a) Expression of ATX-myc and FLAG-tagged PAI-1 in HEK 293 cell 
lysates and in the medium. (b) Immunoprecipitation of ATX-myc from HEK293 cell lysates expressing 
ATX-myc and/or FLAG-PAI-1, as indicated. IPs were immunoblotted for Myc or PAI-1. (c) Total lysates from 
cells expressing ATX-myc or FLAG-PAI-1 were separated by SDS-page and blotted onto a nitrocellulose 
membrane. The membranes were exposed either to medium containing secreted ATX-myc (secreted 
FLAG-PAI-1 was used as a negative control). Binding of ATX-myc to the membrane was assessed by 
immunoblotting using anti-myc antibody.
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ATX binds to activated platelets in a "3 integrin-dependent manner and mediates static 
adhesion of platelets to immobilized ATX24. By analogy with the well characterized vSMB-
mediated interactions with integrins, we considered the possibility that the ATX SMB domains 
also interact with platelet integrins. We found that a truncated protein containing only the two 
ATX SMB domains (53-143, atxSMB) strongly binds to activated human platelets (Fig. 10f,g). 
Binding to the SMB domains is enhanced by stimulating the platelets with ADP or the integrin 
activator Mn+2 and is substantially attenuated by the "3 integrin blocking antibody 7E3 (Fig. 10f). 
Moreover, binding of the isolated SMB domains to platelets is comparable to that of full-length 
ATX, in both avidity and concentration dependence (Fig. 9a). From these results we conclude that 
the N-terminal SMB domains are the primary mediators of the ATX-platelet interaction with "3 
integrins on the agonist-stimulated platelet surface. The atxSMB2 domain contains an integrin-
binding sequence RGD motif (126-128, Fig. 10d,e). However, this motif lies within the atxSMB2 
Fig. 9: wtATX and SMB-ATX domains binding to integrins is concentration dependent. (a) Binding of 
platelets to varying concentrations of immobilized ATX or ATX SMB domain was determined as described 
in the methods. The data are normalized to binding observed with 10mg/ml fibrinogen and are means 
+/- SD of triplicate determinations. (b) Binding of platelets to fibrinogen, hATX and hATX RGD->RGE 
mutant. The data are normalized to binding observed with 10mg/ml fibrinogen and are means +/- SD of 
triplicate determinations. Error bars represent the s.e.m.
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domain, whereas the vitronectin RGD motif is located several residues downstream from its SMB 
domain and is disordered42. In vitronectin, an RGD to RGE mutation disrupts an Asp-mediated 
Mn2+ interaction between the ligand and integrin thereby severely attenuating integrin binding. 
An ATX RGE mutant, however, shows binding to activated platelets indistinguishable from that 
Fig. 10: The SMB domains and integrin-mediated interaction with activated platelets. (a) The structure 
of the vitronectin SMB domain (vSMB) with plasminogen activator inhibitor 1 (PAI-1, PDB:1OC042). The 
SMB domain is shown as a cartoon, colored from purple through blue from the N- to the C-terminus, and 
the Cys-bridges are shown as yellow sticks. PAI-1 is shown as a surface colored aquamarine. The vSMB 
interaction surface with PAI-1 is 656 Å2, making five hydrogen bonds and five salt bridges; (b) vSMB in 
complex with the urokinase-type plasminogen activator receptor (uPAR complex, PDB:3BT143) in light cyan. 
The vSMB interaction surface with uPAR is 620 Å2, making seven hydrogen bonds and five salt bridges; (c) 
The first SMB domain of ATX (atxSMB1) highlighting the interaction with the rest of ATX, shown as a surface 
colored as in Fig.1. The atxSMB1 interaction surface with the PDE is 620 Å2, making nine hydrogen bonds 
and a salt bridge; (d) The second SMB domain (atxSMB2) with the rest of ATX. The atxSMB2 interaction 
surface with the PDE is 571 Å2, but forming only three hydrogen bonds; (e) An alignment of vitronectin and 
ATX SMB sequences; residues involved in interaction with binding partners are in color; the RGD motifs are 
underlined; (f) Binding of wild-type ATX and atxSMB to activated platelets is similar in magnitude, depends 
on Mn+2 and ADP, and can be lowered by interference with an integrin "3 binding antibody. (g) Binding 
of the atxSMB domains to platelets is significantly attenuated by mutation of His-119 to alanine and less 
a"ected by mutation of the RDB motif. All error bars represent the s.e.m.
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of wild-type ATX (Fig. 9b). Binding of platelets to the isolated SMB domains containing an AGA 
mutant (R127A/D129A) showed less binding compared to the wild-type SMB domain protein 
(Fig. 10g and Fig. 11), but did not abolish it as expected. This suggested that the interaction of 
ATX with platelet "3 integrins is mechanistically distinct from the binding of the vitronectin SMB 
domain to these receptors, and involves residues separate from the RGD motif. To examine 
this notion further, we created five additional mutants of the atxSMB2 domain: E110A, R112A, 
H119A, D121A and E122A. Of these, only H119A and E122A were expressed in amounts su#cient 
for purification and further experiments. While E122A abrogated binding to an extent similar 
to that of the AGA mutant, the H119A mutation showed significantly reduced binding. Glu122 
is conserved in the vSMB, while His119 is a Gln (maintaining the nitrogen donor at a similar 
position), and both these residues participate in the interaction of vSMB with PAI-1 and uPAR. 
These experiments confirm that binding of ATX to integrins involves a wider portion of the 
available atxSMB2 surface, which includes His119, Asp122 as well as Asp129.
The SMB domains are involved in LPA binding 
AtxSMB2 abuts the lipid-binding pocket and a nearby narrow tunnel (the ‘white hole’ in Fig. 5h). 
In both crystal forms residual electron density occupies this tunnel (Fig. 12), likely indicating 
the presence of a molecule that we were unable to model, possibly a lipid acquired from the 
growth medium. 
The proximity of the SMB domains to the lipid-binding site and the tunnel raises the 
possibility that they might be involved in product binding and release. To test if the SMB 
domains modulate the enzymatic activity of ATX, we expressed an ATX variant lacking both 
SMB1 and SMB2 (#SMB-ATX; residues 145-863 of hATX). We have previously reported that LPA 
acts as a mixed-type inhibitor of ATX activity against a variety of substrates39. We could thus 
probe the role played by the SMB domains in product binding and release by comparing LPA-
mediated inhibition of nucleotide hydrolysis in wild-type ATX and #SMB-ATX. Both wild-type 
ATX and the #SMB-ATX protein exhibited comparable activity against the classical nucleotide 
substrate pNP-TMP, with k
M
 values of 1.93±0.20 and 2.87±0.9 mM respectively (Fig. 13). However, 
whereas wild-type ATX activity against this substrate was potently inhibited by LPA (18:1) 
Fig. 11: Binding of atxSMB domains and mutants to platelets. In this alternative platelet preparation, 
binding of the atxSMB domains to platelets is attenuated by mutation of the RGD motif, but is totally 
abolished by mutation of His-119 to alanine. All error bars represent the s.e.m..
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(EC
50
 0.08 µM), #SMB-ATX was approximately 10-fold less sensitive (EC
50
 0.72 µM) to inhibition 
by this LPA species (Fig. 7d). These results identify a role for the SMB domains as a determinant 
of the a#nity of the interaction between ATX and LPA, and are consistent with our suggestion 
that SMB2 participates in substrate recognition and/or product release. Processes that impact 
on the interaction between SMB2 and the PDE domain, for example integrin binding, could 
constitute a mechanism for physiological regulation of ATX activity.
DISCUSSION
We have determined the crystal structure of rat ATX and tested the activities of structurally 
guided site- directed mutants in human ATX. Since the enzymes from the two species are 93% 
identical, the biochemical and structural experiments readily complement one another. 
A deep, hydrophobic pocket of the type observed in ATX is a thermodynamically unstable 
structure. We suggest that the formation of strong interactions between the NUC and PDE 
domains during the course of evolution, may have stabilized the fold su#ciently for it to 
accommodate the deletion of eighteen residues (Fig. 1) and the consequent formation of the 
hydrophobic pocket.
The determinants of the substrate specificity of the ENPPs have long been a mystery. 
The ATX structure provides a possible explanation. Both nucleotides and lipids partially share 
the same binding pocket, but the acyl-chain of lipid substrates form additional hydrophobic 
contacts with ATX. This model implies that the LPA product likely has higher a#nity for ATX than 
Fig. 12: Residual electron density near the tunnel in the structure of native ATX. (a) The view and coloring 






 is shown 
as a grey grid contoured at 3.5 rms. (b) The same as in a, looking from the back - the density indicating a 
bound ligand is now visible through the tunnel but the additional electron density is more clear.
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any nucleotide substrate. This hypothesis is consistent with our previous finding that LPA acts 
as an inhibitor of ATX activity against a variety of substrates39, but not of LPC hydrolysis46. Thus, 
LPA formed by the enzyme may act as a “substrate specifying factor” that e"ectively inhibits the 
hydrolysis of nucleotides because it can only be displaced by lysophospholipid substrates such 
as LPC. This mechanism could dictate ATX activity in vivo, because the spectrum of available 
LPA species could define ATX activity against specific lysophospholipid substrates. Our findings 
also suggest that further analysis of structural determinants of substrate discrimination could 
lead to the identification of molecules that inhibit the hydrolysis of specific substrates, e.g. 
long-chain rather than short-chain LPC species.
The ATX SMB domains function as protein interaction modules, mediating platelet 
interaction through integrin binding. However, the binding mode appears to be structurally 
distinct from classical RGD-mediated integrin binding. Instead, ATX-SMB2 may interact with 
integrins using a surface similar to that employed by the related vitronectin SMB domains in 
their interactions with PAI-1 and uPAR.
We also have shown that the SMB domains are important for binding the LPA product 
to ATX, and we speculate that they might be involved in LPA release. In this scenario, SMB-
Fig. 13: Activity of wild-type ATX and #SMB-ATX in pNP-TMP hydrolysis. Observed hydrolysis rates for 
varying substrate concentrations presented in black for wild-type ATX and grey for #SMB-ATX. The same 
data are shown in a linear (top) and logarithmic (bottom) x-axis for clarity. Error bars represent the s.e.m.
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mediated interactions with integrins might not only provide a mechanism for recruiting 
ATX to the cell surface to generate LPA in proximity of its receptors, but could also mediate 
a conformational change to promote product release. Localized LPA production by integrin-
mediated recruitment of ATX (e.g. at the platelet surface) may account for the observed 
increase in plasma LPA levels following platelet activation50. Similar reasoning may also be 
applied to ENPP1, where a natural mutation of lysine 173 (K173Q, often described in literature 
as ‘K121Q’), that is equivalent to the Arg128 of the ATX RGD motif, has severe physiological 
consequences51 suggesting that modulation of integrin binding to the SMB domains through 
such mutations may result in altered ENPP1/2 activities in vivo.
Further structural and biochemical studies examining ATX with its physiological substrates, 
products and specific integrin subunits, will be necessary to unravel how exactly LPA production 
is regulated by ATX.
Accession codes. The models and structure factors for rATX and rATX+HA155 respectively 
are deposited in the PDB with accession codes 2xr9 and 2xrg respectively.
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ABSTRACT
Autotaxin (ATX) is a secreted ecto-nucleotide pyrophosphatase / phosphodiesterase with 
lysophospholipase D activity, producing the signalling lipid lysophosphatidic acid (LPA) from 
lysophosphatidylcholine (LPC). The bimetallic active site of ATX is structurally similar to other 
members of the alkaline phosphatase superfamily. Here, we examine two new crystal structures 
of ATX, namely ATX-VO
5
, a complex of ATX with orthovanadate, and ATX-pThr, where the active 
site nucleophile Thr209 of ATX is phosphorylated. We postulate that both structures mimic 
reaction steps of the substrate hydrolysis by ATX. In the ATX-VO
5
 structure the vanadate anion 
adopts a trigonal bipyramidal conformation and is covalently bound to the O# nucleophile 
of Thr209, mimicking the transition state of the enzymatic reaction after the nucleophilic 
attack onto the substrate. The phosphorylated Thr209 structure likely represents the reaction 
intermediate prior to the second nucleophilic attack of an activated water molecule to form 
the product. These two structures, together with our previous structure of ATX complexed to a 
phosphate ion, o"er three catalytic snapshots. In these structures we observe a movement of 
Thr209 and of the position of the zinc ions relative to each other and to the rest of the active 
site, and the water molecule that likely fulfils the second nucleophilic attack. Our data support 
the concept of an associative two-step in-line displacement mechanism for ATX.
Jens Hausmann, Leonie van Zeijl, Wouter H. Moolenaar & Anastassis Perrakis
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INTRODUCTION
Autotaxin (ATX) is a secreted 100 kDa glycoprotein1. It is a unique member of the ectonucleotide 
pyrophosphatase / phosphodiesterase (ENPP) family2 as it is the only family member that has 
also lysoPLD activity and hydrolyses lysophosphatidylcholine (LPC) into lysophosphatidic acid 
(LPA)3; 4. LPA is a signalling lipid that activates many cellular pathways by binding to specific 
G-protein coupled receptors (LPA
1-6
) (Fig. 1)5. The ATX-LPA signalling axis is implicated in vascular 
and neural development, tumour progression and metastasis, inflammation, fibrotic disease and 
neuropathic pain6; 7. Others and we have recently crystallized and determined the structure of 
ATX8; 9, which shows a compact and robust architecture for a multi-domain protein; it consists 
of four domains, two N-terminal somatomedin-B-like domains, the catalytic phosphodiesterase 
domain (PDE) and an inert nuclease domain (NUC). The crystal structures of ATX showed that 
the architecture of the active site around the Threonine 209 (Thr209) nucleophile, including 




) and their coordination shell, are similar to the closest structural 
homologue of ATX, the nucleotide pyrophosphatase from Xanthomonas axonopodis (XaNPP 
PDB: 2GSO)10. The hydrophilic substrate binding groove is a further conserved structural feature 
of both enzymes. In analogy to XaNPP structure10, this groove should accommodate the ribose 
and base moieties of nucleotide substrates, and in ATX accommodates the glycerol backbone of 
the lipid substrates9. This shallow groove in ATX extends into a deep hydrophobic pocket, which 
is not present in XaNPP, and results from a deletion of an 18 amino acid stretch that is specific 
to ATX within the ENPP family. It has been shown, that this hydrophobic pocket binds the alkyl 
chain of lipid substrates9, as well as the hydrophobic fluoro-benzene ring of HA1558, a nanomolar 
inhibitor of ATX11. In addition, the crystal structures also revealed a unique tunnel, which starts 
from the shallow hydrophilic groove exiting on the opposing side of the PDE domain. This 
tunnel is putatively involved in LPA binding, and has also been suggested by Nishimasu et al. to 
potentially present the LPA product to its cognate receptor9.
The superfamily of alkaline phosphatases groups a diverse set of metalloenzymes12, including 
for example XaNPP10, the name-giving member of this superfamily the alkaline phosphatase 
(AP) of E.coli13, but also ATX14. The AP preferentially hydrolyses phosphomonoesters15, while 
XaNPP preferentially hydrolyses phosphodiesters10; 14, like ATX2. Phosphate monoester and 
diester hydrolysis are considered to follow a two-step in-line displacement mechanism, 
in a dissociative fashion for phosphomonoesterases and in an associative fashion for 





the cleavage of the phosphorus leaving group bond precedes the formation of the new 





no significant bond cleavage to the leaving group occurs while the new bond to the nucleophile 
is established18; 19.
Here, we present two new crystal structures of ATX complexes. The first complex is with 
the transition state mimic orthovanadate and in the second complex the Thr209 nucleophile is 
phosphorylated. We postulate that both structures mimic reaction steps during the catalysis of 
ATX, and based on that information, we propose an associative two-step in-line displacement 
mechanism for the substrate catalysis by ATX.
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MATERIAL AND METHODS
Expression and Purification of rATX for crystallization
Recombinant His-tagged ATX was expressed and purified from HEK293 medium using 
POROS-20 MC columns pre-loaded with Cu2+ as previously published20. Briefly, the column was 
washed with eight to ten column volumes of bu"er A (20 mM HEPES pH 7.4, 150 mM NaCl). ATX 
was eluted with a linear gradient of bu"er B (20 mM HEPES pH 7.4, 150 mM NaCl and 500 mM 
imidazole). Subsequently the recombinant protein was further purified using a Superose 6 
(10/300) gel filtration column. The rATX protein was concentrated to 4.5 mg/ml using a Amicon 
Fig. 1: Schematic presentation of ATX-LPA axis. ATX cleaves the choline headgroup from various LPC 
molecules to produce LPA. LPA can then bind to its cognated G-protein coupled receptors (LPA
1-6
) to 
transduct the signal and triggers cellular responses.
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Ultra 0.5 ml 10 kDa concentrator. The recombinant protein concentration was determined 
using Nanodrop1000. The purity of ATX (<95%) was monitored on a SDS-PAGE.
Expression and Purification of rATX for vanadate inhibition assays
His-tagged rat ATX (isoform 2) from a stable Flp-In cell line was expressed in roller bottles and 
purified from medium using Talon a#nity resin (Clontech) (1 ml slurrie per 50 ml of medium). 
Purified protein was eluted from the beads in 150 mM NaCl/50 mM Hepes/500 mM Imidazole. 
Subsequently, Imidazole was removed by dialysis (150 mM NaCl, 50 mM Hepes). 
ATX/lysoPLD activity assay
ATX lysoPLD activity was measured by the release of choline from LPC 18:1. Briefly, 30 nM ATX 
(863 aa) was incubated with 150 µM LPC 18:1 in Tris-HCl bu"er (pH 7.4), 0.01% (w/v) Triton X-100 at 37 
C. Liberated choline was detected colorimetrically using choline oxidase (1 Unit mL'1), horseradish 





=320/450nm in 96-well plates. Measurements were taken every 90 seconds for 90 minutes. For 




 were used. The maximum velocity of 
each sample was determined by data analysis using prism graph pad software. 
Nucleotide phosphodiesterase assay
ATX nucleotide phosphodiesterase activity was measured colorimetrically using the nucleotide 
derivative pNP-TMP (p-nitrophenyl thymidine 5!-monophosphate) as a substrate. 30 nM ATX 
(recombinant protein like above) was incubated with 1 mM pNP-TMP in Trizma bu"ered saline 
at pH 7.8 in 96-well plates. The amount of liberated para-nitrophenolate (pNP) was determined 









. The maximum velocity of each sample was 
determined by data analysis using prism graph pad software
Crystallization of ATX-VO
5
Crystallization experiment was performed at 293 K using the hanging-drop variant of the 
vapour-di"usion method in Limbro plates as previously published.21 The reservoir solution (1ml) 
consisted of 18% (w/v) PEG 3350, 0.2 M NH
4
I and 0.4 M NaSCN. The drop was made by mixing 1 µl 
of rATX (4.5 mg/ml) pre-incubated with 1 mM orthovanadate and 1 µl of reservoir solution on 
siliconized cover slips (pH: 7.4). Typically after two weeks the first crystals appeared, but had to 
grow for another two weeks to obtain a crystal of 0.05 x 0.05 x 0.02 mm3. Crystals were vitrified 
in reservoir solution with the addition of 20% glyercol and 3.6 mM orthovanadate. 
Crystallization of ATX-pThr
This crystallization experiment was performed in the same setting as above. The reservoir 
solution contained 20% (w/v) PEG 3350, 0.1 M NH
4
I and 0.3 M NaSCN. The drop was made 
by mixing 1 µl of rATX (4.5 mg/ml) pre-incubated with 2mg/ml heparin sulfate and 1 µl of 
reservoir solution (pH: 6.3). After one week the first crystals formed, but they had to grow for 
a couple of more days, to obtain a crystal of O.15 x 0.02 x 0.02 mm3. Crystals were vitrified in 
cryoprotectant, which consisted of reservoir solution with the addition of 20% (v/v) glyercol 
and a final concentration of 2 mg/ml heparin sulfate. 
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Data Collection, Structure Determination, Refinement and Deposition of ATX-VO
5
X-ray di"raction data were collected on X06DA (PXIII) at the SLS at 100° K. The crystallographic 
di"raction data were recorded on a PILATUS detector to a resolution of 2.2 Å. The space group 
was determined as P1 with cell dimension of a=53.8 Å, b=63.5 Å, c=70.6 Å and !=99.3°, "=105.9°, 
#=99.5°. The data were processed with iMOSFLM22 and scaled with SCALA23. The ATX-pThr 
structure was taken as a model for the ATX-VO
5
 structure. These initial coordinates were chosen 
because both structures are in the same space group (P1) and have almost identical unit cell 
dimensions. The structure was solved using Molecular Replacement using PHASER24. All ligands 




 and the Ca site. Manual model 
building and subsequent refinement were performed iteratively with COOT25 and REFMAC526. 




 converged to 0.224/0.259 (Table1). The quality 
of this final structure model was validated with the MolProbidity28 server and ranks in the 99th 
best percentile of PDB structures in this resolution with no Ramachandran outliers. Atomic 
coordinates and experimental structure factors of ATX-VO
5
 have been deposited in PDB database 
under the code XXXX. All presentations of structures within this work were made using PyMol.
Data Collection, Structure Determination, Refinement and Deposition of ATX-pThr
X-ray diffraction data were collected on ID29 at the ESRF 100° K. The crystallographic di"raction data 
were recorded on a PILATUS detector to a resolution of 1.65 Å. The apparent crystal space group 
was P1 with cell dimension of a=53.7 Å, b=63.5 Å, c=70.7 Å and !=98.7°, "=105.8°, #=100.0. All data 
were processed and integrated with XDS29 and scaled with SCALA23. The structure was determined 
by molecular replacement using PHASER24 with four ensemble searches for the PDE-, NUC-, SMB1 
and SMB2 domain. Manual model building and subsequent refinement was performed iteratively 




 converged to 0.184 and 
0.216 (Table 1). The quality of the structure was validated with MolProbidity and ranks in the 91th best 
percentile of PDB structures in this resolution with no Ramachandran outliers. Atomic coordinates 
and experimental structure factors of ATX-pThr have been deposited in PDB under the code XXXX.
NOTE: The ATX-pThr structure was obtained in a co-crystallization approach with unfractionated 
heparin. We detect well-defined sugar-like electron density in the tunnel of the ATX-pThr structure. 
However, since an undefined mixture of heparin sulphate was used and these sugar chains can be 
very divers, it was not possible to model it unambiguously. Noteworthy, a similar density within the 
tunnel at a comparable location is recognizable in ATX-VO
5
 structure, which was not incubated with 
any other ligand than orthovanadate, as well as in the native ATX-PO
4
 structure. The occurrence of 
this ligand electron density must therefore be a co-purified product of the recombinant expression 
of ATX. To model this electron density and to validate, whether this is an artifact or of physiological 
relevance, is beyond scope of this paper, but surely interesting to pursue.
RESULTS & DISCUSSION
Vanadate inhibition data of pNP-TMP and LPC hydrolysis
The vanadate anion closely mimics phosphate, structurally and chemically, and the concept of vanadate 
as a phosphoryl transfer transition state mimic has become widely accepted31; 32. Orthovanadate (VO
4
-3) 
is a well-known micromolar inhibitor for protein tyrosine phosphatases and alkaline phosphatases. 
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To test if this transition metal oxoanion also inhibits the catalytic phosphodiesterase activity of ATX, 
we performed a vanadate inhibition analysis of ATX using lysophosphatidylcholine (LPC 18:1) and the 
nucleotide phosphodiester analogue pNP-TMP as substrates. Our data (Fig. 2) show that, as expected, 
vanadate is a weak inhibitor of both the LPC and pNP-TMP hydrolysis, with K
i
-values of 160 ±50 µM and 
35.0 ±8 µM respectively. These K
i
 values are comparable to reported values in the literature for the 
closely related XaNPP protein10. The inhibitor dissociation constants of vanadate in both assays are in a 
similar range, supporting the notion that orthovanadate functions as a transition state mimic for ATX. 
From that data we concluded that structural complex data of ATX with orthovanadate as a transition 
state mimic would be helpful to characterize the catalytic mechanism in more detail. 
Crystal Structure of ATX with orthovanadate (ATX-VO
5
)
We obtained a 2.2 Å complex structure of ATX with orthovanadate (ATX-VO
5
) and refined it to 
an R
free
 of 0.259. The characteristic trigonal bipyramidal shape of the penta-covalent vanadium, 
which is linked covalently to the enzyme via the O# of Thr209, could be observed in the 
electron density maps (Fig. 3b). The O# atom of Thr209 occupies one of the two axial oxygen 
positions in that configuration. The opposing axial oxygen is 2.6 Å away from the Zn
1
, similar to 
the vanadylated AP structure, where this free axial oxygen is 2.4 Å from the Zn
1
 site33 (PDB: 1B8J). 
The three equatorial oxygens and the vanadium are aligned in a plane. The first equatorial 
vanadate oxygen is coordinated between the two zinc ions, with 1.9 Å to the Zn
1
 and 2.5 Å to the 
Zn
2
 site. The second equatorial oxygen forms hydrogen bonds to the amide nitrogens of the 
backbone of Thr209 and of the side chain of Asn230 (Fig. 4b).
Fig. 2: Michaelis-Menten vanadate inhibition analysis of (a) LPC (18:1) and (b) pNP-TMP hydrolysis catalyzed 
by ATX.
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Fig. 3: Stereo images showing close-up views of the active site of ATX. The structure of ATX is shown 
as transparent ribbon presentation in light green. Active site residues and ligands are depicted as sticks 












 electron density map presented as grey mesh at 3.5& in the ATX-VO
5
 structure before modeling 




 electron density map obtained from the ATX-pThr structure, 
before modeling the phosphorylated Thr209, depicted at 3.5& as grey mesh.
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Fig. 4: Schematic presentation of the active site from (a) the ATX-PO
4
, (b) the ATX-VO
5
 and (c) the ATX-pThr 
structure. The active site side chain of Thr209 is colored in dark blue and its backbone in black, the bound 
phosphate and the covalently bound phosphate are shown in red, and the vanadate ion is presented in light 
blue. Hypothesized R and R’-groups are added in purple. Atomic interactions are depicted as dashed lines.





Space group P1 P1
Cell dimensions
    a, b, c(Å) 53.8, 63.5, 70.6 53.7, 63.5, 70.7
    !, ", #(°) 99.4, 105.9, 99.5 98.7, 105.8, 100.0
Resolution (Å)a 40-2.20 (2.32-2.20) 44-1.65 (1.74-1.65)
R
merge
a 0.116 (0.825) 0.059 (0.619)
I / &(I) 4.9 (1.4) 7.9 (1.2)
Completeness (%)a 90.2 (90.7) 92.5 (91.6)
Redundancya 1.6 (1.7) 2.0 (2.0)
Refinement
Resolution (Å) 40-2.20 44-1.65





 (%) 22.4/25.9 18.4/21.6
No. atoms 
    Protein 6281 6384
    Ligand/Ion/Glycan 35 39
    Water 138 469
B-factors 
    Protein 37.7 28.2
    Ligand/Ion/Glycan 29.4 29.0
    Water 32.5 30.5
R.m.s. deviations 
    Bond lengths (Å) 0.016 0.019
    Bond angles (°) 1.92 1.66
aData in parentheses correspond to the highest resolution shell.
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The third equatorial oxygen does not appear to make any specific bonds with the protein. 
The geometry of orthovanadate mimicking transition states, is represented with great variety 
in the PDB database32. Generally it can be divided into distorted or non-distorted trigonal 
bipyramidal geometry. The vanadate anion was observed to be distorted with an angle between 
the axial oxygens of 157° for XaNPP (PDB: 2GSO) and of 172° for AP10; 33 (PDB: 1B8J). Since our 
vanadate complex data are only of medium resolution (2.2 Å) and the vanadate geometry was 
restrained it is hard to conclude about the nature of these bonds; however, no clear evidence 
of distortion was evident in the electron density maps. 
Crystal Structure of ATX with a phosphorylated Thr209 (ATX-pThr) 
We obtained a 1.65 Å complex structure of ATX (ATX-pThr) and refined it to an R
free
 of 0.216. Here, 
we observed additional electron density extending from the O# of Thr209 into the active site, 
but in a tetrahedral shape, which suggests the presence of a phosphorylated Thr209 (Fig 3c). 
This complex has been crystallized in more acidic conditions (pH: 6.3) compared to previous
 
crystallization conditions (pH: 7.4); at that pH the hydrolysis of the phosphorylated active site 
becomes rate-limiting at acid pH and allowed trapping of this intermediate in our structure34; 35.
We were able to identify only two structures of phosphorylated active site nucleophiles from 
the AP superfamily exist in the PDB. However, both structures are made with mutant versions of 
the AP phosphomonoesterase. In the first structure the Zn
1
 coordinating histidine (His331) was 
mutated to glutamine (PDB: 1HJK) and in the second one the serine nucleophile (Ser102) was 
substituted for a threonine36; 37 (PDB: 2GA3). Thus this structure is the first to show a phosphorylated 
active site intermediate for a phosphodiesterase member of the AP superfamily.
In this structure we observe a water network in the active site. The core of this network 
consists of five water molecules, which interact with the protein via hydrogen bonds to Asp473, 
Asn230 and Lys208. The most intriguing water molecule of this network is the W
1 
molecule, 
which is 2.2 Å from the Zn
1
 (Fig 3c). This water is suitably oriented to fulfil a water-based 
nucleophilic attack on the phosphorous atom of the phosphorylated Thr209, as it is expected 





 and ATX-pThr structures 
The ATX-VO
5
 and ATX-pThr structures constitute two snapshots of the catalysis by ATX. In our first 
structure of ATX (PDB: 2XR9, ATX-PO4 therein), we have observed a phosphate ion close to Thr209 
(Fig 3a and Fig 4a). The ATX-PO4 structure provides a third snapshot that mimics the substrate 
bound state, the first step in the reaction sequence of ATX. Collectively, ATX-PO4, ATX-VO
5
 and 
the ATX-pThr structures mimic consecutive reaction steps during the catalysis by ATX and allow a 
more detailed description of the two-step catalytic mechanism that has been put forward14.




 and ATX-pThr protein structures show they are 
overall nearly identical with RMSD of 0.39 Å over 771 aligned C! atoms (calculated by the 
RAPIDO server)38 and demonstrate no significant conformational domain changes of ATX 
during catalysis. However, the three structures have a wealth of local changes that allows to 
follow the catalytic mechanism in more detail.
In the ATX-PO4 structure, the zinc ions are 4.3 Å from each other and each is bound to 
the phosphate oxygen that represent the attachment positions of the R and R’ groups of the 
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 is activating the O#'of the threonine nucleophile that is 1.6 Å from it. The 
third oxygen, presumably the one that has a partial negative charge in the alkaline pH that 
the reaction takes place, is bound to the amine group of Asn230, that is characteristic of the 
phosphodiester but not the monoester cleaving enzymes39. The fourth oxygen, the one bearing 
to the double bond to the phosphate, is not constrained by any interactions. 
In the next step, likely represented by the ATX-VO
5
 structure, one equatorial oxygen atom of 
the vanadate, representing the free oxygen in the real substrate, is inserted between the two zinc 
ions almost in the same line as the one connecting the two zinc ions that are still 4.3 Å from each 
other. This oxygen is now significantly closer to the Zn
1
 (1.9 Å) rather than the Zn
2 
(2.7 Å). The axial 
oxygen where the R leaving group of the substrate would normally lie, is now far from the Zn
1
 and 
would thus allow the first product to depart. As the R group leaves we move to the next step that is 
represented by the ATX-pThr structure. Here, the two zinc ions are further apart, 4.5 Å from each 
other. The phosphate oxygen now moves away from the line connecting the two zincs, and it is 
significantly further away from Zn
1 
(2.7 Å) than in the previous step (1.9 Å). In proximity to the Zn
1 
is in that structure the water molecule (W1, 2.2 Å) that likely comes into place to fulfil the second 
nucleophilic displacement event and facilitate the departure of the R’ leaving group. 
The most prominent change in these catalytic snapshots is however the movement of the 
active site side chain of Thr209. The +
1
 of Thr209 in the ATX-PO
4
 structure is -87°, while the +
1
 of 
Thr209 in the ATX-VO
5
 structure is -58° and in the ATX-pThr structure -59°, respectively. These 
di"erent +
1 
angles translate into a 1.8 Å movement of the O# of Thr209 towards the Zn
1
 in the 
ATX-VO
5 
structure relative to the ATX-PO
4
 structure (Fig. 4), while at the same time it moves away 
from the Zn
2 
atom. In the ATX-pThr structure the O# of Thr209 moves 0.4 Å backwards relative to 
the observed position in the ATX-VO
5
 structure. The di"erence in the +
1
 angles do not reflect the 
observed 0.4 Å movement of the O# of Thr209, but this movement is mediated by changes along 
the backbone. A similar albeit smaller movement of the active site nucleophile has also been 
observed in the vanadate AP complex structure33 (PDB: 1B8J). In this structure the nucleophile of 
Ser102 had moved 0.8 Å towards the Zn
1
 site compared to the non-covalently bound phosphate 
complex13; 33 (PDB: 1ALK). The close distance of the O# nucleophile to Zn
2
 is important to allow it to 
perform the nucleophilic attack. It remains to be investigated if movements of the same magnitude 
are also taking place when the actual substrate hydrolysis takes place, but our observations are 
well in line with the well-established first nucleophilic attack and can serve well to rearrange the 
positioning of the intermediate to come in place for the second nucleophilic attack. 
Mechanistic Implications for Catalysis by ATX 
Phosphodiesterases are considered to have an associative mechanism, where no significant 
bond cleavage of the leaving group occurs while the new bond to the nucleophile is 
established25; 26. The transition-state mimic structure of ATX-VO
5
 strongly suggests an 
associative catalytic mechanism for ATX, as it is of a pentacovalent nature. According to this 
scenario, the phosphorous atom of the substrate is nucleophilically attacked by the O# of 
Thr209, which leads to the destabilization of the double-bonded oxygen and the formation 
of a pentacovalent transition state. The bond between the phosphorous atom and the oxygen 
atom, which bridges the R-group, is then cleaved, allowing departure of the R-group. The 
next reaction step in the mechanism is the nucleophilic water-based attack on the substrate-
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nucleophile intermediate, to form the product and release the R group. Our ATX-pThr structure 
likely represents the reaction state prior to the attack on the phosphorylated Thr209. The Zn
1
 
coordinated water molecule is optimally positioned to fulfil this nucleophilic bimolecular S
N
2 
attack on the intermediate. The stereochemistry of the phosphate ion supports this concept, 
as it could be inverted between the ATX-PO
4
 and the ATX-pThr structure (Fig. 5). 
CONCLUSIONS
We presented two crystal structures of ATX that we postulate they represent snapshots of the 
ATX catalytic cycle. The ATX-VO
5
 structure mimics the transition state of the enzymatic reaction 
after the nucleophilic attack onto the substrate. The transition state analogue orthovanadate 
adopts in this structure a pentacovalent cofiguration. The ATX-pThr structure represents the 
reaction state prior to the second nucleophilic attack of an activated water molecule on the 
phosphorylated Thr209 to form the product. We observe specific conformational changes in 
the active site of these structures, which likely facilitate the positioning of the real substrates 
for catalysis. Our structures support the concept of an associative two-step in-line mechanism 
for the substrate hydrolysis by ATX.
Fig. 5: Suggested catalytic mechanism of ATX.
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The present thesis concerns the structure of autotaxin (ATX) alone and in complex with a 
small-molecule inhibitor (HA155), as well as its biochemical characterization. ATX was originally 
discovered as an “autocrine motility factor” from melanoma cells, more than two decades 
ago, but its biochemical function remained elusive. It took another decade to show that ATX 
functions as a lysophospholipase D that generates the lipid growth factor LPA. It is now know 
that ATX is essential for embryonic development, while numerous studies associate the ATX-LPA 
signaling axis with various diseases, including cancer, fibrosis, neuropathic pain and immune-
mediated diseases1. This makes ATX and interesting target for therapeutic intervention, and 
pharmaceutical companies and academia invest great e"ort into the development of ATX 
inhibitors; the number of ATX inhibitors is increasing steadily. Insight into the structure of ATX 
will help to accelerate the development of ATX inhibitors as therapeutic agents. Here I briefly 
summarize and discuss the results of my thesis work. 
Crystallization and Structure Determination of ATX
To optimize crystallisation conditions for a large protein like ATX, basic requirements towards sample 
preparation have to be met. The protein sample has to be expressed in high quantity and quality. 
Mammalian cell expression systems allow large-scale production of secreted proteins2, such as ATX. 
Combining this approach with the Flp-InTM technology3, optimizes the time- and cost-e#ciency 
even further, as intensive preparation labour for transient transfection is omitted and reproducibility 
of the expression is more reliable. Under these conditions, enzymatically active ATX (from rat) was 
expressed in amounts suitable for crystallisation experiments (chapter 2). 
The sample used in crystallisation screens has usually more than 95% purity and has to 
be concentrated to 5-10 mg/ml. The introduction of a size exclusion chromatography step 
improved the sample purity and revealed new crystallisation conditions. Further optimization 
(by adding 0.3 M sodium thiocyanate) yielded crystals that di"racted to high resolution 
The size and shape of the crystal and the experimental set-up provided by individual 
synchrotron beam lines are important parameters for structure determination. The development 
of tuneable microfocus beams with di"erent beam sizes in combination with a grid-scan 
procedure, o"ers the possibility to optimize data collection from thin plate-like crystals 
(Chapter 2)4. Changes in crystal size that appear during data collection could be accounted for 
by three-dimensional data collection software, which considers the volume, the variation of 
beam sizes and exposure times, to routinely collect data with higher e#ciency (Chapter 2).
The structure of ATX
To understand the function of ATX in more detail, the full length structure of rat ATX alone 
and in complex with the inhibitor HA155 were determined (Chapter 3). The structures obtained 
gave important new insights into the domain organization of ATX and ATX catalysis, however 
they also gave rise to new questions.
The crystal structure revealed that the catalytic PDE domain is the central element of the 
domain architecture of ATX. The N-terminal SMB1 and SMB2 domains are located on one side of 
the PDE domain. On the opposite side, the C-terminal NUC domain forms a large interface with 
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the central PDE domain. The close relative of ATX, ENPP1, also possesses this large interface 
between the PDE and NUC domain, but the SMB domains of ENPP1 show a complete di"erent 
orientation and a higher degree of flexibility compared to the SMB domains of ATX. These 
observations suggest functional di"erences between the SMB domains of ENPP1 and ATX. 
The catalytic site of ATX is similar to that in ENPP1 and other members of the alkaline 
phosphatase superfamily5. We could show that residue Asn230 is crucial for catalysis by 
ATX. In the alkaline phosphatase of E. coli this asparagine is exchanged for an arginine 
(Chapter 4). Interestingly, the latter enzyme is a phosphomonosterase, suggesting that the 
substrate specificity is alternated by the substitution of asparagine to arginine, as indicated by 
others6. It would be of interest to examine how an Asn230 to arginine mutant of ATX would alter 
phosphomonesterase vs. phosphodiesterase activity.
The crystal structures of ATX revealed a hydrophobic pocket, which is adjacent to the active 
site and not present in ENPP15. The biochemical analysis of ATX mutants, described in Chapter 3, 
suggests that the pocket accommodates the aliphatic chain of lipid substrates. This conclusion 
is supported by concurrent crystallographic complex data of ATX with various LPA species, 
where the aliphatic chains are bound in the pocket7. Additionally, the hydrophobic pocket has 
been observed to be lockable by the fluorobenzene ring of HA155. However, it would be of 
great interest to see where and how other inhibitors, such as PF8380, bind to ATX and how they 
generate their specificity towards ATX.
An open tunnel near the hydrophobic pocket of ATX was an unexpected and intriguing 
observation in the crystal structure. The tunnel is formed by a tight interaction between the 
PDE and SMB domains and adjacent to both the hydrophobic pocket and the active site. The 
tunnel might be involved in product release or substrate entry (Chapter3). However, so far 
neither crystallographic nor biochemical data could hint at a functional role for the tunnel. 
Therefore, the function of the tunnel remains elusive. It is not known if newly formed LPA is 
released from ATX and if LPA is specifically targeted to its receptors8. Further studies should 
address the concept of a complex between ATX and its cognate LPA receptors (LPA
1-6
), as well 
as the possible involvement of the tunnel in the delivery of LPA.
Further questions that arise from the crystal structure concern the binding of substrates, 
such as LPC, ATP, and FS3, for the catalysis by ATX. The key questions here are: how do these 
ligands bind exactly, how is the leaving group orientated? Is the tunnel also involved in the 
binding of either substrate or product? To address these questions, it will be necessary to use 
catalytically inactive ATX in co-crystallization experiments with substrates.
ATX Interaction with the cell surface
Cells achieve specificity in their signaling networks by organizing discrete subsets of proteins 
in space and time9. A spatial and temporal recruitment of ATX to LPA-responsive cells can 
be achieved via the interaction with cell-surface molecules. The binding of ATX to cell-
surface integrins described in Chapter 3 and elsewhere10, is an important observation for the 
understanding of ATX-driven LPA signaling. The results in Chapter 3 show that ATX binds to 
integrin "3 subunits via its N-terminal SMB domains. Recently it was shown that the G-protein 
subunit G!13 binds to "3 of the platelet integrin !IIb"3 and thereby triggers an inside-out 
signaling event, leading the modulation of ligand binding a#nity. Interestingly, G!13 is coupled 
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could stimulate G!13 dependent inside-out signaling via !IIb"3, which might alter the binding 
specificity of ATX to !IIb"3. Future investigations should test hypothesis.
Moreover, ATX immobilization can also be achieved by binding to the cell-surface heparan 
sulfate proteoglycans. This binding appears to be isoform-specific, as only the ATX! isoform 
is a heparin-binding protein (Houben et al., JBC 288: 510-519, 2013). Thus, ATX can use distinct 
mechanisms to bind to target cells and deliver LPA to the cell surface. 
PERSPECTIVES 
ATX is a fascinating and vital enzyme for life that is involved in many biological processes with 
its intrinsic capability to generate LPA under physiological and pathophysiological conditions. 
Due to the recent structural insights of ATX, we start to understand more and more the biology 
of ATX and the implied LPA axis. Additionally, the determination of the ENPP1 structure and 
hopefully more members of the ENPP family will deepen our knowledge about the biochemical 
specificity of these family members in general and for ATX in particular. The ever increasing 
list of publications on the ATX-LPA signaling axis reflect the enormous scientific e"orts that 
are undertaken to understand this signaling axis in more detail, in order to address it with 
therapeutic intervention in the near future.
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Autotaxin (ATX) werd meer dan twee decennia geleden ontdekt als een “autocrine motility 
factor” a(omstig van melanomacellen, maar de precieze biochemische functie van ATX was in 
eerste instantie onbekend. Het duurde echter nog ruim een decennium voordat duidelijk werd 
dat ATX een lysofosfolipase D is  dat zorgt voor de productie van lysofosfatidezuur (LPA), een 
lipide groeifactor, en vrij choline door de hydrolyse van lysofosfatidylcholine (LPC). Tegenwoordig 
weten we dat ATX essentieel is voor de embryonale  ontwikkeling, terwijl talrijke onderzoeken 
de ATX-LPA “signaal-as” associëren met verschillende aandoeningen, waaronder kanker, fibrose, 
neuropathische pijn en auto-immuun ziektes zoals reumatoïde arthritis en chronische ontsteking. 
ATX is derhalve een belangrijk doelwit voor therapeutische interventie, en zowel de farmaceutische 
industrie als de academische wereld hebben veel middelen ingezet voor de ontwikkeling van ATX 
remmers. Dit proefschrift bevat de structurele en biochemische karakterisatie van ATX. 
Het eerste hoofdstuk is een algemene introductie tot ATX met nadruk op destructuur-
functie relaties van het enzym. Het tweede hoofdstuk beschrijft methodes voor de 
expressie en  opzuivering van ATX in hoeveelheden en kwaliteit die geschikt zijn voor zowel 
Röntgenkristallografie als voor datacollectie van microkristallen. Verder worden geavanceerde 
datacollectie strategieën behandeld voor dunne plaatachtige kristallen. 
Het derde hoofdstuk bevat de structurele analyse van ATX in zijn apo-vorm en in complex met de 
potente remmer HA155. Verder beschrijft dit hoofdstulk hoe ATX de diverse substraten 
onderscheidt en hydrolyseert. Bovendien laten we zien hoe ATX aan bloedplaatjes bindt via 
integrine "3 op het celoppervlak.
Het vierde hoofdstuk beschrijft de katalytische mechanisme van ATX in verder detail met 
behulp van Röntgenkristallografie De resultaten ondersteunen het concept van een “associative 
two-step in-line  displacement mechanism” voor ATX. 
De verkregen resultaten verscha"en nieuwe inzichten in de functie van ATX en de ATX-LPA 
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